shrnas target specific Search Results


90
Shanghai GenePharma shrnas specifically targeting chicken akt
Shrnas Specifically Targeting Chicken Akt, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/shrnas+specifically+targeting+chicken+akt/pm35795905-86-1-29
Average 90 stars, based on 1 article reviews
shrnas specifically targeting chicken akt - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem human hsdl2-specific targeting sequence
Human Hsdl2 Specific Targeting Sequence, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/a+small+hairpin+rna++shrna++targeting+hsdl2+with+high+specificity/pmc06566746-23-1-26
Average 90 stars, based on 1 article reviews
human hsdl2-specific targeting sequence - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem sirna specific for tug1
<t>TUG1</t> Was Upregulated in Bladder Cancer, and Its Expression Was Correlated with Clinicopathological Characteristics (A) The expression of TUG1 among urological cancers, including bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), and testicular germ cell tumors (TGCT) from The Cancer Genome Atlas (TCGA) Data Portal from GEPIA ( http://gepia.cancer-pku.cn/ ). The expression of TUG1 in normal or cancer is shown with green or red dots. (B) The expression of TUG1 in normal and bladder cancer from TCGA Data Portal. (C) The expression of TUG1 was evaluated by real-time PCR in bladder cancer tissues; GAPDH was used for internal control. p < 0.05. (D) The expression of TUG1 was evaluated by real-time PCR in bladder cancer cell lines. *p < 0.05. (E) Kaplan-Meier survival curves for patients with bladder cancer according to the expression level of TUG1. (F) Bladder cancer samples with higher tumor stage (T2-T3) showed upregulated expression of TUG1 compared to that of lower tumor stage (Ta-T1). p < 0.05. (G) Bladder cancer samples with lymph node metastasis showed upregulated expression of TUG1. p < 0.05.
Sirna Specific For Tug1, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/shrna+that+specifically+targeted+tug1++shtug1+/pmc06439231-193-4-12
Average 90 stars, based on 1 article reviews
sirna specific for tug1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Obio Technology Corp Ltd retroviral particles
Differential expression of <t>Mettl1</t> and Wdr4 during neurogenesis . ( A, B ) Immunofluorescence staining for Mettl1 and Wdr4 in Nestin + NSCs, Tuj1 + neurons and GFAP + astrocytes. Scale bar, 150 μm. ( C, D ) Western blotting and quantification for Mettl1 in NSCs, neurons and astrocytes. n = 3, *** P < 0.001 compared with NSCs. ( E, F ) Western blot and quantification for Wdr4 in NSCs, neurons and astrocytes. n = 3, *** P < 0.001, * P < 0.05 compared with NSCs. ( G, H ) The expressions of Mettl1 and Wdr4 mRNA in NSCs, neurons and astrocytes. n = 3, *** P < 0.001 compared with NSCs. ( I ) Immunofluorescence staining for Mettl1 costaining with Nestin, NeuN and GFAP in dentate gyrus of hippocampus. Scale bar, 200 μm. Data are represented as the mean ± SEM. NSCs, neural stem cells; n represents number of independent experiments
Retroviral Particles, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/mettl1+specific+shrna++targetseq1+cccacactttaagcgaacgaa++target+seq2+gccatgaaacaccttcctaat++retroviral+particles/pmc10544167-48-10-16
Average 90 stars, based on 1 article reviews
retroviral particles - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma sirnas for rab3d
(A). Western Blot analysis of intracellular <t>Rab3D</t> expression in HMEC, non-invasive breast cancer MCF-7, and invasive SKBr-3, MDA-MB-231 cell lines. (B). Western Blot analysis of intracellular Rab3D expression in melanoma F0, F1, F10 cell lines. (C) Western Blot analysis of intracellular Rab3D expression in lung cancer A549, H-1299 cell lines and ovary cancer Hela cell line. (D). Representative Rab3D staining in normal tissues, benign tumor and malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (E). Association of Rab3D immunohistochemical scores with tumor malignancy. The x 2 test was used to test difference between categorical variables. (F). Representative Rab3D staining in different stages of malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (G). Associations of Rab3D immunohistochemical scores with tumor stage (I, II, III-IV) and tumor grade (1, 2, and 3). The x 2 test was used to test difference between categorical variables.
Sirnas For Rab3d, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/short+hairpin+rna++shrna++specifically+targeting+rab3d/pmc04484444-157-3-7
Average 90 stars, based on 1 article reviews
sirnas for rab3d - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma shrnas specifically targeting linc00519
(A). Western Blot analysis of intracellular <t>Rab3D</t> expression in HMEC, non-invasive breast cancer MCF-7, and invasive SKBr-3, MDA-MB-231 cell lines. (B). Western Blot analysis of intracellular Rab3D expression in melanoma F0, F1, F10 cell lines. (C) Western Blot analysis of intracellular Rab3D expression in lung cancer A549, H-1299 cell lines and ovary cancer Hela cell line. (D). Representative Rab3D staining in normal tissues, benign tumor and malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (E). Association of Rab3D immunohistochemical scores with tumor malignancy. The x 2 test was used to test difference between categorical variables. (F). Representative Rab3D staining in different stages of malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (G). Associations of Rab3D immunohistochemical scores with tumor stage (I, II, III-IV) and tumor grade (1, 2, and 3). The x 2 test was used to test difference between categorical variables.
Shrnas Specifically Targeting Linc00519, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/shrnas+specifically+targeting+linc00519/10__2147_slash_ott__s279798-97-6-15
Average 90 stars, based on 1 article reviews
shrnas specifically targeting linc00519 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Eurofins specific shrnas targeting mybl2
a , Crossing gene expression microarrays of A673 EwS cells, harboring a DOX-inducible shRNA against EWSR1-FLI1 (A673/TR/shEF1) profiled with/without addition of DOX, with 166 transcriptomes of primary EwS tumors with matched clinical annotation, reveals <t>MYBL2</t> as the top EWSR1-FLI regulated gene associated with poor patient outcome. b , Kaplan-Meier plot of overall survival in a cohort of 166 primary EwS patients for which Affymetrix gene expression data and clinical annotations were available. Patients were stratified by quintile MYBL2 expression. Mantel-Haenszel-Test. c , Western blot using antibodies against EWSR1-FLI1 and MYBL2 in A673/TR/shEF1 cells. EWSR1-FLI1 was knocked down for 7 days by DOX-treatment and re-expressed by removing DOX from the media for 10 days. β-actin served as loading control. d , Epigenetic profile of the MYBL2 locus inA673 and SK-N-MC EwS cells. Signals from published DNAse-Seq data (DNAse I hypersensitivity; HS) and ChIP-seq data for EWSR1-FLI1, H3K4me1 and H3K27ac in EwS cells transfected with either a control shRNA (shGFP) or a specific shRNA against EWSR1-FLI1 (shEF1) are displayed. e , Luciferase reporter assay after cloning haplotypes of the MYBL2-associated GGAA-microsatellite (mSat) from different cell lines into a pGL3 expression vector. The vectors were transfected in A673/TR/shEF1 cells, which were treated either with or without DOX. Data are mean and SEM, n=4. Unpaired student’s t-test. f , Analysis of relative MYBL2 expression in RDES EwS cells after CRISPRi-mediated blockage of protein binding to the MYBL2-associated GGAA-microsatellite. Data are mean and SEM, n =4. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.
Specific Shrnas Targeting Mybl2, supplied by Eurofins, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/specific+shrnas+targeting+mybl2/bio_rxiv__506659-79-11-15
Average 90 stars, based on 1 article reviews
specific shrnas targeting mybl2 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem lentiviral particles equipped with the corresponding short hairpin rnas (shrnas) specifically targeting pou1f1
Expression pattern of <t>POU1F1</t> in stem cell‐like cells of GC. (A) Analysis of the capacity of self‐renewal among PAMC‐82, SNU16 parental cells, and spheroids. (B and C) Expression levels of stem cell markers including CD44, Oct4, Sox2, and Nanog in PAMC‐82 and SNU‐16 cells, as well as their spheroids were detected using qRT‐PCR and western blotting analysis, respectively. (D) Western blotting was performed to validate the expression levels of stem cell marker, Sox4. (E and F) Expression status of POU1F1 mRNA and protein was determined using qRT‐PCR and western blotting assays among PAMC‐82 and SNU‐16 parental cells, compared with their spheroids, respectively. β‐Actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.
Lentiviral Particles Equipped With The Corresponding Short Hairpin Rnas (Shrnas) Specifically Targeting Pou1f1, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/lentiviral+particles+equipped+with+the+corresponding+short+hairpin+rnas++shrnas++specifically+targeting+pou1f1/pmc11895930-27-14-20
Average 90 stars, based on 1 article reviews
lentiviral particles equipped with the corresponding short hairpin rnas (shrnas) specifically targeting pou1f1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Eurofins specific shrnas targeting ramp1
a Analysis of cell growth and cell death of A673 and RDES EwS cells with/without siRNA- or shRNA-mediated knockdown of <t>CALCB</t> . Left panel A673 and RDES: Given is the mean of relative cell count compared to Co (Control), which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible <t>shRNAs</t> ( n = 3–5). SEM and unpaired two-tailed Student’s t test of relative total cell count. Right panel A673 and RDES: Knockdown of CALCB was verified by qRT-PCR. Given is the mean gene expression and SEM; unpaired two-tailed Student’s t test. b Colony-forming assays of A673 and RDES EwS cells with/without siRNA- or dox-induced shRNA-mediated knockdown of CALCB or RAMP1 . Mean colony number and SEM normalized to control, which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs ( n = 3–6). Unpaired two-tailed Student’s t test. Representative images of each condition are shown. Knockdown of CALCB and RAMP1 were verified by qRT-PCR and are displayed in Fig. 4a and Supplementary Fig. . c Sphere-formation assays of A673 and RDES EwS cells with/without dox-induced shRNA-mediated knockdown of CALCB and RAMP1 . Sphere index was calculated by addition of diameter of all existing spheres in one well divided by diameter of spheres in the control well. Mean and SEM ( n = 3–6); unpaired two-tailed Student’s t test. n.s. P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001
Specific Shrnas Targeting Ramp1, supplied by Eurofins, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/specific+shrnas+targeting+ramp1/pmc06370763-91-25-31
Average 90 stars, based on 1 article reviews
specific shrnas targeting ramp1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma the lentiviral vector carrying specific p53-targeting shrna
Downregulated BMAL1 promoted <t>p53</t> <t>expression</t> in T2DM. (A) Protein expression of BMAL1, p53 and p21 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs as determined by western blot. (B) qRT-PCR analysis of BMAL1, p53 and p21 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs. (C) Immunofluorescence staining of p53 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs. Scale bars: 100 µm. All data are mean±s.e.m. and representative of three independent experiments. n =3. β-actin was used as a loading control. Statistical significance was defined as * P <0.05; ** P <0.01.
The Lentiviral Vector Carrying Specific P53 Targeting Shrna, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/the+lentiviral+vector+carrying+specific+p53+targeting+shrna/pmc07358138-193-5-10
Average 90 stars, based on 1 article reviews
the lentiviral vector carrying specific p53-targeting shrna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Igene Biotechnology Inc short hairpin rna (shrna) sequences specifically targeting krt17
<t>KRT17</t> expression levels in PAC tissue samples. (A) Quantitative PCR results demonstrated significantly increased expression levels of KRT17 mRNA in PAC tissues compared with adjacent normal tissues. n=18. (B) Bioinformatics analysis revealed that the expression levels of KRT17 were higher in T compared with N tissues. (C) Immunohistochemical staining from The Human Protein Atlas demonstrated higher KRT17 expression levels in PAC compared with normal samples. (D and E) Kaplan-Meier survival analyses from the GEPIA website showed that (D) overall survival and (E) disease-free survival of patients with high expression levels of KRT17 were significantly lower compared with those with low expression levels of KRT17 in PAC. *P<0.05, ***P<0.001. KRT17, Keratin 17; PAC, pancreatic cancer; T, tumor; N, normal; HR, hazard ratio.
Short Hairpin Rna (Shrna) Sequences Specifically Targeting Krt17, supplied by Igene Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/short+hairpin+rna++shrna++sequences+specifically+targeting+krt17/pmc07114934-63-8-33
Average 90 stars, based on 1 article reviews
short hairpin rna (shrna) sequences specifically targeting krt17 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Transomic Technologies Inc lentiviral particles pzip-hcmv-zsgreen-puro-itga4 shrna
<t>KRT17</t> expression levels in PAC tissue samples. (A) Quantitative PCR results demonstrated significantly increased expression levels of KRT17 mRNA in PAC tissues compared with adjacent normal tissues. n=18. (B) Bioinformatics analysis revealed that the expression levels of KRT17 were higher in T compared with N tissues. (C) Immunohistochemical staining from The Human Protein Atlas demonstrated higher KRT17 expression levels in PAC compared with normal samples. (D and E) Kaplan-Meier survival analyses from the GEPIA website showed that (D) overall survival and (E) disease-free survival of patients with high expression levels of KRT17 were significantly lower compared with those with low expression levels of KRT17 in PAC. *P<0.05, ***P<0.001. KRT17, Keratin 17; PAC, pancreatic cancer; T, tumor; N, normal; HR, hazard ratio.
Lentiviral Particles Pzip Hcmv Zsgreen Puro Itga4 Shrna, supplied by Transomic Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrnas+target+specific/itga4+specific+targeting+shrna+lentiviral+particles+pzip+hcmv+zsgreen+puro+itga4+shrna/pmc09083130-79-10-32
Average 90 stars, based on 1 article reviews
lentiviral particles pzip-hcmv-zsgreen-puro-itga4 shrna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


TUG1 Was Upregulated in Bladder Cancer, and Its Expression Was Correlated with Clinicopathological Characteristics (A) The expression of TUG1 among urological cancers, including bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), and testicular germ cell tumors (TGCT) from The Cancer Genome Atlas (TCGA) Data Portal from GEPIA ( http://gepia.cancer-pku.cn/ ). The expression of TUG1 in normal or cancer is shown with green or red dots. (B) The expression of TUG1 in normal and bladder cancer from TCGA Data Portal. (C) The expression of TUG1 was evaluated by real-time PCR in bladder cancer tissues; GAPDH was used for internal control. p < 0.05. (D) The expression of TUG1 was evaluated by real-time PCR in bladder cancer cell lines. *p < 0.05. (E) Kaplan-Meier survival curves for patients with bladder cancer according to the expression level of TUG1. (F) Bladder cancer samples with higher tumor stage (T2-T3) showed upregulated expression of TUG1 compared to that of lower tumor stage (Ta-T1). p < 0.05. (G) Bladder cancer samples with lymph node metastasis showed upregulated expression of TUG1. p < 0.05.

Journal: Molecular Therapy. Nucleic Acids

Article Title: lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

doi: 10.1016/j.omtn.2019.02.017

Figure Lengend Snippet: TUG1 Was Upregulated in Bladder Cancer, and Its Expression Was Correlated with Clinicopathological Characteristics (A) The expression of TUG1 among urological cancers, including bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), and testicular germ cell tumors (TGCT) from The Cancer Genome Atlas (TCGA) Data Portal from GEPIA ( http://gepia.cancer-pku.cn/ ). The expression of TUG1 in normal or cancer is shown with green or red dots. (B) The expression of TUG1 in normal and bladder cancer from TCGA Data Portal. (C) The expression of TUG1 was evaluated by real-time PCR in bladder cancer tissues; GAPDH was used for internal control. p < 0.05. (D) The expression of TUG1 was evaluated by real-time PCR in bladder cancer cell lines. *p < 0.05. (E) Kaplan-Meier survival curves for patients with bladder cancer according to the expression level of TUG1. (F) Bladder cancer samples with higher tumor stage (T2-T3) showed upregulated expression of TUG1 compared to that of lower tumor stage (Ta-T1). p < 0.05. (G) Bladder cancer samples with lymph node metastasis showed upregulated expression of TUG1. p < 0.05.

Article Snippet: Prevalidated siRNA specific for TUG1 and corresponding siRNA control were purchased from Genechem (Shanghai, China).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Control

miR-194-5p Could Be Negatively Regulated by TUG1 (A) The expression of miR-194-5p was negatively correlated with that of TUG1. (B) The efficiency of TUG1 silencing in short hairpin RNA stably transduced bladder cancer cell lines 5637 and T24. (C) The expression of miR-194-5p in bladder cancer cell lines T24 and 5637 after transfecting with sh-TUG1 or sh-LacZ by real-time PCR. p < 0.01. (D) Luciferase reporters harboring putative target sites in the 3′ UTR of TUG1 were co-transfected with 100 nM of the indicated small RNA molecules (wild-type or mutant miR-94-5p) in T24 and 5637 cells. *p < 0.01. Relative luciferase activity was plotted as the mean ± SEM of three independent experiments. (E) The amount of miR-194-5p and TUG1 bound to AGO2 was measured by qPCR in nuclear and total fractions in the presence of miR-194-5p mimics or mimic NC. (F) Methylation-specific PCR was performed using primers specific for the unmethylated (U) or methylated (M) miR-194-5p promoter region in the genomic DNA deriving from bladder cell lines and tissues. (G) miR-194-5p expression in 4 bladder cancer cell lines after 5-Aza-DC or mock treatment. *p < 0.05. (H) Western blot showed that EZH2 protein level was attenuated following the knockdown of TUG1 in bladder cancer cells. (I) Western blot indicated that EZH2 protein was effectively abrogated following specific siRNA or DZNep treatment. (J) qRT-PCR results indicated that miR-194-5p was significantly induced following the knockdown of EZH2. (K) Methylation-specific PCR showed that knockdown of EZH2 by siRNAs or DZNep relieved the promoter hypermethylation of miR-194-5p.

Journal: Molecular Therapy. Nucleic Acids

Article Title: lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

doi: 10.1016/j.omtn.2019.02.017

Figure Lengend Snippet: miR-194-5p Could Be Negatively Regulated by TUG1 (A) The expression of miR-194-5p was negatively correlated with that of TUG1. (B) The efficiency of TUG1 silencing in short hairpin RNA stably transduced bladder cancer cell lines 5637 and T24. (C) The expression of miR-194-5p in bladder cancer cell lines T24 and 5637 after transfecting with sh-TUG1 or sh-LacZ by real-time PCR. p < 0.01. (D) Luciferase reporters harboring putative target sites in the 3′ UTR of TUG1 were co-transfected with 100 nM of the indicated small RNA molecules (wild-type or mutant miR-94-5p) in T24 and 5637 cells. *p < 0.01. Relative luciferase activity was plotted as the mean ± SEM of three independent experiments. (E) The amount of miR-194-5p and TUG1 bound to AGO2 was measured by qPCR in nuclear and total fractions in the presence of miR-194-5p mimics or mimic NC. (F) Methylation-specific PCR was performed using primers specific for the unmethylated (U) or methylated (M) miR-194-5p promoter region in the genomic DNA deriving from bladder cell lines and tissues. (G) miR-194-5p expression in 4 bladder cancer cell lines after 5-Aza-DC or mock treatment. *p < 0.05. (H) Western blot showed that EZH2 protein level was attenuated following the knockdown of TUG1 in bladder cancer cells. (I) Western blot indicated that EZH2 protein was effectively abrogated following specific siRNA or DZNep treatment. (J) qRT-PCR results indicated that miR-194-5p was significantly induced following the knockdown of EZH2. (K) Methylation-specific PCR showed that knockdown of EZH2 by siRNAs or DZNep relieved the promoter hypermethylation of miR-194-5p.

Article Snippet: Prevalidated siRNA specific for TUG1 and corresponding siRNA control were purchased from Genechem (Shanghai, China).

Techniques: Expressing, shRNA, Stable Transfection, Real-time Polymerase Chain Reaction, Luciferase, Transfection, Mutagenesis, Activity Assay, Methylation, Western Blot, Knockdown, Quantitative RT-PCR

Knockdown of TUG1 Inhibited Cell Proliferation, Induced Apoptosis, and Sensitized Bladder Cancer Cells to Cisplatin (A) MTS assays revealed cell growth curves of the indicated cells. (B) Representative micrographs of crystal violet-stained cell colonies analyzed by colony formation. (C–E) Photographs of tumors (C) excised 37 days after inoculation of stably transfected T24 cells into nude mice. Mean tumor volume (D) measured by caliper on the indicated days and tumor weight (E) of each nude mice at the end of 37 days are shown. p < 0.01. (F) Apoptosis detection after treating with sh-TUG1, cisplatin, and sh-TUG1 + cisplatin in bladder cancer cell lines T24 and 5637. p < 0.01. (G) The change of IC 50 after transfecting sh-TUG1 into bladder cancer cell lines T24 and 5637. p < 0.01. (H) MTS assays revealed cell growth curves of the indicated cells. (I) The expression of TUG1 was evaluated by real-time PCR in bladder cancer cell lines T24 and 5637 after treatment with cisplatin. (J) The inhibition ratio detection after treatment with sh-TUG1 or sh-TUG1 + cisplatin in bladder cancer cell lines T24 and 5637. p < 0.01. (K) Photographs of tumors excised 37 days after the inoculation of stably transfected T24 cells into nude mice. Mean tumor volume measured by caliper on the indicated days and tumor weight of each nude mice at the end of 37 days are shown. p < 0.01.

Journal: Molecular Therapy. Nucleic Acids

Article Title: lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

doi: 10.1016/j.omtn.2019.02.017

Figure Lengend Snippet: Knockdown of TUG1 Inhibited Cell Proliferation, Induced Apoptosis, and Sensitized Bladder Cancer Cells to Cisplatin (A) MTS assays revealed cell growth curves of the indicated cells. (B) Representative micrographs of crystal violet-stained cell colonies analyzed by colony formation. (C–E) Photographs of tumors (C) excised 37 days after inoculation of stably transfected T24 cells into nude mice. Mean tumor volume (D) measured by caliper on the indicated days and tumor weight (E) of each nude mice at the end of 37 days are shown. p < 0.01. (F) Apoptosis detection after treating with sh-TUG1, cisplatin, and sh-TUG1 + cisplatin in bladder cancer cell lines T24 and 5637. p < 0.01. (G) The change of IC 50 after transfecting sh-TUG1 into bladder cancer cell lines T24 and 5637. p < 0.01. (H) MTS assays revealed cell growth curves of the indicated cells. (I) The expression of TUG1 was evaluated by real-time PCR in bladder cancer cell lines T24 and 5637 after treatment with cisplatin. (J) The inhibition ratio detection after treatment with sh-TUG1 or sh-TUG1 + cisplatin in bladder cancer cell lines T24 and 5637. p < 0.01. (K) Photographs of tumors excised 37 days after the inoculation of stably transfected T24 cells into nude mice. Mean tumor volume measured by caliper on the indicated days and tumor weight of each nude mice at the end of 37 days are shown. p < 0.01.

Article Snippet: Prevalidated siRNA specific for TUG1 and corresponding siRNA control were purchased from Genechem (Shanghai, China).

Techniques: Knockdown, Staining, Stable Transfection, Transfection, Expressing, Real-time Polymerase Chain Reaction, Inhibition

CCND2 Was a Bona Fide Target of miR-194-5p, and TUG1 Upregulated CCND2 Level in Bladder Cancer (A) The expression of CCND2 mRNA in bladder cancer cell lines T24 and 5637 after transfection with miR-194-5p was detected by real-time PCR. (B) The expression of CCND2 protein in bladder cancer cell lines T24 and 5637 after transfection with miR-194-5p was detected by western blot. (C) Luciferase reporter assay was conducted to determine if miR-194-5p could bind to the wild-type or mutant 3′ UTR of CCND2. Relative luciferase activity was plotted as the mean ± SEM of three independent experiments. (D) The positive correlation between the expression level of TUG1 and CCND2 in bladder cancer tissues. p < 0.05. (E) Western blot results showed the protein expression of CCND2 in bladder cancer cell lines T24 and 5637 after transfecting with shRNAs for TUG1 or sh-LacZ. (F) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after transfection with shRNAs for TUG1 or sh-LacZ by real-time PCR. p < 0.01. (G) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after co-transfecting with sh-TUG1 or sh-LacZ or miR-194-5p inhibitor or negative control for inhibitor by western blot. (H) The proliferation assays were performed to evaluate the effect of TUG1 on the miR-194-5p-CCND2 axis. (I) Luciferase reporter assay showed that knockdown of the expression of TUG1 partially abrogated the promotion of the luciferase signal by miR-194-5p inhibitor. (J) Luciferase reporter assay showed that knockdown of the expression of TUG1 and overexpression of miR-194-5p decreased the luciferase signal further.

Journal: Molecular Therapy. Nucleic Acids

Article Title: lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

doi: 10.1016/j.omtn.2019.02.017

Figure Lengend Snippet: CCND2 Was a Bona Fide Target of miR-194-5p, and TUG1 Upregulated CCND2 Level in Bladder Cancer (A) The expression of CCND2 mRNA in bladder cancer cell lines T24 and 5637 after transfection with miR-194-5p was detected by real-time PCR. (B) The expression of CCND2 protein in bladder cancer cell lines T24 and 5637 after transfection with miR-194-5p was detected by western blot. (C) Luciferase reporter assay was conducted to determine if miR-194-5p could bind to the wild-type or mutant 3′ UTR of CCND2. Relative luciferase activity was plotted as the mean ± SEM of three independent experiments. (D) The positive correlation between the expression level of TUG1 and CCND2 in bladder cancer tissues. p < 0.05. (E) Western blot results showed the protein expression of CCND2 in bladder cancer cell lines T24 and 5637 after transfecting with shRNAs for TUG1 or sh-LacZ. (F) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after transfection with shRNAs for TUG1 or sh-LacZ by real-time PCR. p < 0.01. (G) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after co-transfecting with sh-TUG1 or sh-LacZ or miR-194-5p inhibitor or negative control for inhibitor by western blot. (H) The proliferation assays were performed to evaluate the effect of TUG1 on the miR-194-5p-CCND2 axis. (I) Luciferase reporter assay showed that knockdown of the expression of TUG1 partially abrogated the promotion of the luciferase signal by miR-194-5p inhibitor. (J) Luciferase reporter assay showed that knockdown of the expression of TUG1 and overexpression of miR-194-5p decreased the luciferase signal further.

Article Snippet: Prevalidated siRNA specific for TUG1 and corresponding siRNA control were purchased from Genechem (Shanghai, China).

Techniques: Expressing, Transfection, Real-time Polymerase Chain Reaction, Western Blot, Luciferase, Reporter Assay, Mutagenesis, Activity Assay, Negative Control, Knockdown, Over Expression

TUG1 Positively Regulated the Expression of CCND2 by Rescue Assays (A) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after co-transfection with sh-TUG1 and Lenti-CCND2 was detected by real-time PCR. p < 0.01. (B) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after co-transfection with sh-TUG1 and Lenti-CCND2 was detected by western blot. (C) MTS assays revealed cell growth curves of the indicated cells. (D) The change of IC 50 after co-transfection of sh-TUG1 and Lenti-CCND2 in bladder cancer cell lines T24 and 5637. p < 0.01. (E) Apoptosis detection after co-transfection of sh-TUG1 and Lenti-CCND2 in bladder cancer cell lines T24 and 5637. p < 0.01. (F) Representative micrographs of crystal violet-stained cell colonies analyzed by clongenic formation. (G) Photographs of tumors excised 37 days after inoculation of stably transfected T24 cells into nude mice. Mean tumor volume was measured by caliper on the indicated days. p < 0.01.

Journal: Molecular Therapy. Nucleic Acids

Article Title: lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

doi: 10.1016/j.omtn.2019.02.017

Figure Lengend Snippet: TUG1 Positively Regulated the Expression of CCND2 by Rescue Assays (A) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after co-transfection with sh-TUG1 and Lenti-CCND2 was detected by real-time PCR. p < 0.01. (B) The expression of CCND2 in bladder cancer cell lines T24 and 5637 after co-transfection with sh-TUG1 and Lenti-CCND2 was detected by western blot. (C) MTS assays revealed cell growth curves of the indicated cells. (D) The change of IC 50 after co-transfection of sh-TUG1 and Lenti-CCND2 in bladder cancer cell lines T24 and 5637. p < 0.01. (E) Apoptosis detection after co-transfection of sh-TUG1 and Lenti-CCND2 in bladder cancer cell lines T24 and 5637. p < 0.01. (F) Representative micrographs of crystal violet-stained cell colonies analyzed by clongenic formation. (G) Photographs of tumors excised 37 days after inoculation of stably transfected T24 cells into nude mice. Mean tumor volume was measured by caliper on the indicated days. p < 0.01.

Article Snippet: Prevalidated siRNA specific for TUG1 and corresponding siRNA control were purchased from Genechem (Shanghai, China).

Techniques: Expressing, Cotransfection, Real-time Polymerase Chain Reaction, Western Blot, Staining, Stable Transfection, Transfection

Model of TUG1- and miR-194-5p-Dependent Regulation of the Chemoresistance A higher level of TUG1 can directly bind to and function as a biological sponge for mature miR-194-5p, which lowers the expression level of miR-194-5p. Besides, miR-194-5p expression is regulated by promoter methylation; hypermethylation of miR-194-5p promoter also lowers its cellular concentration. TUG1 also induces the expression of EZH2 and further lowers the miR-194-5p via promoter hypermethylation. Moreover, a lower level of miR-194-5p results in higher levels of CCND2 mRNA and protein, which promote the chemoresistance of bladder cancer cells to cisplatin. This could also explain why miR-194-5p is induced by cisplatin treatment.

Journal: Molecular Therapy. Nucleic Acids

Article Title: lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

doi: 10.1016/j.omtn.2019.02.017

Figure Lengend Snippet: Model of TUG1- and miR-194-5p-Dependent Regulation of the Chemoresistance A higher level of TUG1 can directly bind to and function as a biological sponge for mature miR-194-5p, which lowers the expression level of miR-194-5p. Besides, miR-194-5p expression is regulated by promoter methylation; hypermethylation of miR-194-5p promoter also lowers its cellular concentration. TUG1 also induces the expression of EZH2 and further lowers the miR-194-5p via promoter hypermethylation. Moreover, a lower level of miR-194-5p results in higher levels of CCND2 mRNA and protein, which promote the chemoresistance of bladder cancer cells to cisplatin. This could also explain why miR-194-5p is induced by cisplatin treatment.

Article Snippet: Prevalidated siRNA specific for TUG1 and corresponding siRNA control were purchased from Genechem (Shanghai, China).

Techniques: Expressing, Methylation, Concentration Assay

Differential expression of Mettl1 and Wdr4 during neurogenesis . ( A, B ) Immunofluorescence staining for Mettl1 and Wdr4 in Nestin + NSCs, Tuj1 + neurons and GFAP + astrocytes. Scale bar, 150 μm. ( C, D ) Western blotting and quantification for Mettl1 in NSCs, neurons and astrocytes. n = 3, *** P < 0.001 compared with NSCs. ( E, F ) Western blot and quantification for Wdr4 in NSCs, neurons and astrocytes. n = 3, *** P < 0.001, * P < 0.05 compared with NSCs. ( G, H ) The expressions of Mettl1 and Wdr4 mRNA in NSCs, neurons and astrocytes. n = 3, *** P < 0.001 compared with NSCs. ( I ) Immunofluorescence staining for Mettl1 costaining with Nestin, NeuN and GFAP in dentate gyrus of hippocampus. Scale bar, 200 μm. Data are represented as the mean ± SEM. NSCs, neural stem cells; n represents number of independent experiments

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Differential expression of Mettl1 and Wdr4 during neurogenesis . ( A, B ) Immunofluorescence staining for Mettl1 and Wdr4 in Nestin + NSCs, Tuj1 + neurons and GFAP + astrocytes. Scale bar, 150 μm. ( C, D ) Western blotting and quantification for Mettl1 in NSCs, neurons and astrocytes. n = 3, *** P < 0.001 compared with NSCs. ( E, F ) Western blot and quantification for Wdr4 in NSCs, neurons and astrocytes. n = 3, *** P < 0.001, * P < 0.05 compared with NSCs. ( G, H ) The expressions of Mettl1 and Wdr4 mRNA in NSCs, neurons and astrocytes. n = 3, *** P < 0.001 compared with NSCs. ( I ) Immunofluorescence staining for Mettl1 costaining with Nestin, NeuN and GFAP in dentate gyrus of hippocampus. Scale bar, 200 μm. Data are represented as the mean ± SEM. NSCs, neural stem cells; n represents number of independent experiments

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Quantitative Proteomics, Immunofluorescence, Staining, Western Blot

Mettl1 promotes neuronal differentiation of NSCs. . ( A,B ) Western blotting and RT-qPCR of Mettl1 expression in NSCs treated with Mettl1 shRNAs. n = 3, *** P < 0.001, ** P < 0.01 compared with control. ( C-F ) Immunofluorescence staining and quantification for Tuj1, GFAP and EdU on NSCs treated with control or Mettl1 shRNA. Scale bar, 200 μm. n = 3, *** P < 0.001, ** P < 0.01 compared with control. ( G,H ) Western blotting and RT-qPCR of Mettl overexpression in NSCs. n = 3, *** P < 0.001 compared with control. ( I-L ) Immunofluorescence staining and quantification for Tuj1, GFAP and EdU on NSCs treated with control or Mettl1 overexpression. Scale bar, 200 μm. n = 3, *** P < 0.001, ** P < 0.01 compared with control. Data are represented as the mean ± SEM. NSCs, neural stem cells; Sh-Mettl1, shRNA Mettl1; OE-Mettl1, overexpressing Mettl1; n represents number of independent experiments

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Mettl1 promotes neuronal differentiation of NSCs. . ( A,B ) Western blotting and RT-qPCR of Mettl1 expression in NSCs treated with Mettl1 shRNAs. n = 3, *** P < 0.001, ** P < 0.01 compared with control. ( C-F ) Immunofluorescence staining and quantification for Tuj1, GFAP and EdU on NSCs treated with control or Mettl1 shRNA. Scale bar, 200 μm. n = 3, *** P < 0.001, ** P < 0.01 compared with control. ( G,H ) Western blotting and RT-qPCR of Mettl overexpression in NSCs. n = 3, *** P < 0.001 compared with control. ( I-L ) Immunofluorescence staining and quantification for Tuj1, GFAP and EdU on NSCs treated with control or Mettl1 overexpression. Scale bar, 200 μm. n = 3, *** P < 0.001, ** P < 0.01 compared with control. Data are represented as the mean ± SEM. NSCs, neural stem cells; Sh-Mettl1, shRNA Mettl1; OE-Mettl1, overexpressing Mettl1; n represents number of independent experiments

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Western Blot, Quantitative RT-PCR, Expressing, Control, Immunofluorescence, Staining, shRNA, Over Expression

Mettl1 modulates the transcriptome landscape of internal m 7 G-modified mRNA during neurogenesis . ( A, B ) RNA dot blot analysis of m 7 G levels in NSCs, astrocytes and neurons. n = 3, * P < 0.05 compared with NSCs (100 ng); ## P < 0.01 compared with NSCs (200 ng). ( C, D ) RNA dot blot analysis of m 7 G levels in NSCs treated with Mettl1 shRNAs. n = 3, *** P < 0.001 compared with NSCs (100 ng); ### P < 0.001 compared with NSCs (200 ng). ( E, F ) RNA dot blot analysis of m 7 G levels in NSCs treated with Mettl1 overexpression. n = 3, *** P < 0.001 compared with NSCs (100 ng); ## P < 0.01 compared with NSCs (200 ng). ( G ) Distribution of internal m 7 G across NSCs, neurons and astrocytes mRNA segments. ( H ) Pie charts presenting the fraction of m 7 G peaks in NSCs, neurons and astrocytes. ( I ) Motif analysis of internal mRNA m 7 G in NSCs, neurons and astrocytes mRNAs ( J, K ) Bar plot chart showing the significant GO terms and KEGG analysis for NSCs and differentiated neurons mRNAs containing internal m 7 G. ( L ) Volcano plot of significantly altered internal mRNA m 7 G peaks in NSCs compared to neurons. NSCs, neural stem cells; Neu, neurons; Ast, astrocytes. Data are represented as the mean ± SEM. NSCs, neural stem cells; Sh-Mettl1, shRNA Mettl1; OE-Mettl1, overexpressing Mettl1; n represents number of independent experiments

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Mettl1 modulates the transcriptome landscape of internal m 7 G-modified mRNA during neurogenesis . ( A, B ) RNA dot blot analysis of m 7 G levels in NSCs, astrocytes and neurons. n = 3, * P < 0.05 compared with NSCs (100 ng); ## P < 0.01 compared with NSCs (200 ng). ( C, D ) RNA dot blot analysis of m 7 G levels in NSCs treated with Mettl1 shRNAs. n = 3, *** P < 0.001 compared with NSCs (100 ng); ### P < 0.001 compared with NSCs (200 ng). ( E, F ) RNA dot blot analysis of m 7 G levels in NSCs treated with Mettl1 overexpression. n = 3, *** P < 0.001 compared with NSCs (100 ng); ## P < 0.01 compared with NSCs (200 ng). ( G ) Distribution of internal m 7 G across NSCs, neurons and astrocytes mRNA segments. ( H ) Pie charts presenting the fraction of m 7 G peaks in NSCs, neurons and astrocytes. ( I ) Motif analysis of internal mRNA m 7 G in NSCs, neurons and astrocytes mRNAs ( J, K ) Bar plot chart showing the significant GO terms and KEGG analysis for NSCs and differentiated neurons mRNAs containing internal m 7 G. ( L ) Volcano plot of significantly altered internal mRNA m 7 G peaks in NSCs compared to neurons. NSCs, neural stem cells; Neu, neurons; Ast, astrocytes. Data are represented as the mean ± SEM. NSCs, neural stem cells; Sh-Mettl1, shRNA Mettl1; OE-Mettl1, overexpressing Mettl1; n represents number of independent experiments

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Modification, Dot Blot, Over Expression, shRNA

Internal mRNA m 7 G promotes Sptbn2 stability and translation . ( A ) Integrative Genomics Viewer (IGV) tracks displaying m 7 G reads from NSCs, neurons and astrocytes. ( B-E ) Immunofluorescence staining, Western blotting and RT-qPCR of Sptbn2 expression in NSCs, neurons and astrocytes. Scale bar, 150 μm, n = 3, *** P < 0.001, ** P < 0.01, * P < 0.05 compared with NSCs. ( F-I ) The expression of Sptbn2 protein and mRNA in NSCs transfected with the depletion or overexpression of Mettl1. n = 3, *** P < 0.001 compared with control. ( J, K ) Sptbn2 mRNA stability was determined by qRT-PCR in control and NSCs transfected with the depletion or overexpression of Mettl1 using the samples treated with ActD at the indicated times. n = 3, * P < 0.05 compared with control. ( L ) Polysome profiling of NSCs with or without Mettl1 knockdown. Data are represented as the mean ± SEM. NSCs, neural stem cells; Sh-Mettl1, shRNA Mettl1; OE-Mettl1, overexpressing Mettl1; ActD, actinomycin D; n represents number of independent experiments

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Internal mRNA m 7 G promotes Sptbn2 stability and translation . ( A ) Integrative Genomics Viewer (IGV) tracks displaying m 7 G reads from NSCs, neurons and astrocytes. ( B-E ) Immunofluorescence staining, Western blotting and RT-qPCR of Sptbn2 expression in NSCs, neurons and astrocytes. Scale bar, 150 μm, n = 3, *** P < 0.001, ** P < 0.01, * P < 0.05 compared with NSCs. ( F-I ) The expression of Sptbn2 protein and mRNA in NSCs transfected with the depletion or overexpression of Mettl1. n = 3, *** P < 0.001 compared with control. ( J, K ) Sptbn2 mRNA stability was determined by qRT-PCR in control and NSCs transfected with the depletion or overexpression of Mettl1 using the samples treated with ActD at the indicated times. n = 3, * P < 0.05 compared with control. ( L ) Polysome profiling of NSCs with or without Mettl1 knockdown. Data are represented as the mean ± SEM. NSCs, neural stem cells; Sh-Mettl1, shRNA Mettl1; OE-Mettl1, overexpressing Mettl1; ActD, actinomycin D; n represents number of independent experiments

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Immunofluorescence, Staining, Western Blot, Quantitative RT-PCR, Expressing, Transfection, Over Expression, Control, Knockdown, shRNA

Sptbn2 mediates Mettl1-induced neurogenesis . ( A, B ) Western blotting and RT-qPCR of Sptbn2 to validate the knockdown efficiency in NSCs. ** P < 0.01, *** P < 0.001 compared with Vector. ( C-F ) Immunofluorescence staining and quantification for Tuj1, GFAP, and EdU on NSCs treated with overexpressing Mettl1 or shRNA Sptbn2. Scale bar, 200 μm. n = 3, * P < 0.05, ** P < 0.01 compared with Mettl1 overexpression. ( G, H ) Western blotting and RT-qPCR of Sptbn2 to confirm the overexpression efficiency in NSCs. ** P < 0.01 compared with Vector. ( I-L ) Immunofluorescence staining and quantification for Tuj1, GFAP, and EdU on NSCs treated with shRNA Mettl1 or overexpressing Sptbn2. Scale bar, 200 μm. n = 3, ** P < 0.01, *** P < 0.001 compared with shRNA Mettl1. Data are represented as the mean ± SEM. Sh-Mettl1, shRNA Mettl1; Sh-Sptbn2, shRNA Sptbn2; OE-Mettl1, overexpressing Mettl1; OE-Sptbn2, overexpressing Sptbn2; n represents number of independent experiments

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Sptbn2 mediates Mettl1-induced neurogenesis . ( A, B ) Western blotting and RT-qPCR of Sptbn2 to validate the knockdown efficiency in NSCs. ** P < 0.01, *** P < 0.001 compared with Vector. ( C-F ) Immunofluorescence staining and quantification for Tuj1, GFAP, and EdU on NSCs treated with overexpressing Mettl1 or shRNA Sptbn2. Scale bar, 200 μm. n = 3, * P < 0.05, ** P < 0.01 compared with Mettl1 overexpression. ( G, H ) Western blotting and RT-qPCR of Sptbn2 to confirm the overexpression efficiency in NSCs. ** P < 0.01 compared with Vector. ( I-L ) Immunofluorescence staining and quantification for Tuj1, GFAP, and EdU on NSCs treated with shRNA Mettl1 or overexpressing Sptbn2. Scale bar, 200 μm. n = 3, ** P < 0.01, *** P < 0.001 compared with shRNA Mettl1. Data are represented as the mean ± SEM. Sh-Mettl1, shRNA Mettl1; Sh-Sptbn2, shRNA Sptbn2; OE-Mettl1, overexpressing Mettl1; OE-Sptbn2, overexpressing Sptbn2; n represents number of independent experiments

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Western Blot, Quantitative RT-PCR, Knockdown, Plasmid Preparation, Immunofluorescence, Staining, shRNA, Over Expression

Mettl1 knockdown elicits reduced neurogenesis and cognitive impairment in mice . (A-D ) Representative fluorescence images and quantification for BrdU and DCX after Mettl1 shRNA retrovirus infection. Scale bar, 250 μm. *** P < 0.001 compared with vector (control). ( E ) The escape latency in the navigation test. ** P < 0.01 compared with vector (control). ( F ) The number of target crossings where the platform had been located in the probe test. * P < 0.05 compared with vector (control). ( G ) Quadrant time (%) in the probe test. ** P < 0.01 compared with vector (control). ( H ) Representative swimming paths in each quadrant during the probe trial. ( I ) The average swimming speed between the two groups. n = 8 mice per group. Data are represented as the mean ± SEM. Sh-Mettl1, shRNA Mettl1

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Mettl1 knockdown elicits reduced neurogenesis and cognitive impairment in mice . (A-D ) Representative fluorescence images and quantification for BrdU and DCX after Mettl1 shRNA retrovirus infection. Scale bar, 250 μm. *** P < 0.001 compared with vector (control). ( E ) The escape latency in the navigation test. ** P < 0.01 compared with vector (control). ( F ) The number of target crossings where the platform had been located in the probe test. * P < 0.05 compared with vector (control). ( G ) Quadrant time (%) in the probe test. ** P < 0.01 compared with vector (control). ( H ) Representative swimming paths in each quadrant during the probe trial. ( I ) The average swimming speed between the two groups. n = 8 mice per group. Data are represented as the mean ± SEM. Sh-Mettl1, shRNA Mettl1

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Knockdown, Fluorescence, shRNA, Infection, Plasmid Preparation, Control

Mettl1 overexpression rescues the decreased neurogenesis and cognitive deficit in APP/PS1 mice . ( A ) Representative fluorescence images for Mettl1 in the NSCs of hippocampus. Scale bar, 200 μm. ( B-E ) Representative fluorescence images and quantification for BrdU and DCX after retrovirus-mediated Mettl1 overexpression. Scale bar, 250 μm. *** P < 0.001, ** P < 0.01. ( F ) The escape latency in the navigation test. * P < 0.05 compared with AD + vector. ( G ) Quadrant time (%) in the probe test. ** P < 0.01. ( H ) The number of target crossings where the platform had been located in the probe test. *** P < 0.001, ** P < 0.01. ( I ) The average swimming speed among the groups. ( J ) Representative swimming paths in each quadrant during the probe trial. n = 8 mice per group. Data are represented as the mean ± SEM. AD, Alzheimer’s disease (APP/PS1 mice); OE-Mettl1, overexpressing Mettl1

Journal: Cell & Bioscience

Article Title: Mettl1-mediated internal m 7 G methylation of Sptbn2 mRNA elicits neurogenesis and anti-alzheimer’s disease

doi: 10.1186/s13578-023-01131-2

Figure Lengend Snippet: Mettl1 overexpression rescues the decreased neurogenesis and cognitive deficit in APP/PS1 mice . ( A ) Representative fluorescence images for Mettl1 in the NSCs of hippocampus. Scale bar, 200 μm. ( B-E ) Representative fluorescence images and quantification for BrdU and DCX after retrovirus-mediated Mettl1 overexpression. Scale bar, 250 μm. *** P < 0.001, ** P < 0.01. ( F ) The escape latency in the navigation test. * P < 0.05 compared with AD + vector. ( G ) Quadrant time (%) in the probe test. ** P < 0.01. ( H ) The number of target crossings where the platform had been located in the probe test. *** P < 0.001, ** P < 0.01. ( I ) The average swimming speed among the groups. ( J ) Representative swimming paths in each quadrant during the probe trial. n = 8 mice per group. Data are represented as the mean ± SEM. AD, Alzheimer’s disease (APP/PS1 mice); OE-Mettl1, overexpressing Mettl1

Article Snippet: Mettl1-specific shRNA (TargetSeq1 CCCACACTTTAAGCGAACGAA, Target Seq2 GCCATGAAACACCTTCCTAAT) retroviral particles and retrovirus overexpressing Mettl1 were obtained from OBiO Technology (Shanghai) Co., Ltd. 1 μl of retroviral solution with a titer of 2☓10 8 units/ml was injected at a rate of 0.1 μl/min into the bilateral hippocampal dentate gyrus (2.0 mm posterior to the bregma, ± 1.5 mm lateral to the midline, 2.0 mm deep from the top of the skull).

Techniques: Over Expression, Fluorescence, Plasmid Preparation

(A). Western Blot analysis of intracellular Rab3D expression in HMEC, non-invasive breast cancer MCF-7, and invasive SKBr-3, MDA-MB-231 cell lines. (B). Western Blot analysis of intracellular Rab3D expression in melanoma F0, F1, F10 cell lines. (C) Western Blot analysis of intracellular Rab3D expression in lung cancer A549, H-1299 cell lines and ovary cancer Hela cell line. (D). Representative Rab3D staining in normal tissues, benign tumor and malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (E). Association of Rab3D immunohistochemical scores with tumor malignancy. The x 2 test was used to test difference between categorical variables. (F). Representative Rab3D staining in different stages of malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (G). Associations of Rab3D immunohistochemical scores with tumor stage (I, II, III-IV) and tumor grade (1, 2, and 3). The x 2 test was used to test difference between categorical variables.

Journal: Oncotarget

Article Title: High expression of small GTPase Rab3D promotes cancer progression and metastasis

doi:

Figure Lengend Snippet: (A). Western Blot analysis of intracellular Rab3D expression in HMEC, non-invasive breast cancer MCF-7, and invasive SKBr-3, MDA-MB-231 cell lines. (B). Western Blot analysis of intracellular Rab3D expression in melanoma F0, F1, F10 cell lines. (C) Western Blot analysis of intracellular Rab3D expression in lung cancer A549, H-1299 cell lines and ovary cancer Hela cell line. (D). Representative Rab3D staining in normal tissues, benign tumor and malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (E). Association of Rab3D immunohistochemical scores with tumor malignancy. The x 2 test was used to test difference between categorical variables. (F). Representative Rab3D staining in different stages of malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (G). Associations of Rab3D immunohistochemical scores with tumor stage (I, II, III-IV) and tumor grade (1, 2, and 3). The x 2 test was used to test difference between categorical variables.

Article Snippet: The siRNAs for Rab3D were purchased from GenePharma.

Techniques: Western Blot, Expressing, Staining, Immunohistochemical staining

(A). The effect of Rab3D on cytoskeletal rearrangements. Control and siRab3D MDA-MB-231 cells were kept in serum and then fixed. Membrane ruffles formation was analyzed by confocal microscope using a Rhodamine labeled phalloidin antibody to visualize actin cytoskeleton. Scale bar, 50 μm. (B). The effect of overexpressing Rab3D on tumor cell morphology. MCF-7 cells transiently transfected with GFP or GFP-Rab3D-expressing plasmid. Nuclei were stained with DAPI and actin was stained with Rhodamine labeled phalloidin antibody. (C). The effect of different Rab3D mutants on tumor cell morphology. Rab3D (Green), Actin (Red), DAPI (Blue). Scare: 50 μm.

Journal: Oncotarget

Article Title: High expression of small GTPase Rab3D promotes cancer progression and metastasis

doi:

Figure Lengend Snippet: (A). The effect of Rab3D on cytoskeletal rearrangements. Control and siRab3D MDA-MB-231 cells were kept in serum and then fixed. Membrane ruffles formation was analyzed by confocal microscope using a Rhodamine labeled phalloidin antibody to visualize actin cytoskeleton. Scale bar, 50 μm. (B). The effect of overexpressing Rab3D on tumor cell morphology. MCF-7 cells transiently transfected with GFP or GFP-Rab3D-expressing plasmid. Nuclei were stained with DAPI and actin was stained with Rhodamine labeled phalloidin antibody. (C). The effect of different Rab3D mutants on tumor cell morphology. Rab3D (Green), Actin (Red), DAPI (Blue). Scare: 50 μm.

Article Snippet: The siRNAs for Rab3D were purchased from GenePharma.

Techniques: Control, Membrane, Microscopy, Labeling, Transfection, Expressing, Plasmid Preparation, Staining

(A). Down-regulation of Rab3D markedly repressed tumor cells migration (wound healing assays). Representative images and quantification of migration assay in Rab3D knockdown MDA-MB-231 cells (Scale bar, 200 μm) or A375 cells (Scale bar, 50 μm). ** p < 0.01, *** p < 0.001. (B). Down-regulation of Rab3D inhibited the invasion capability of tumor cells on Matrigel-coated transwell insets in the invasion assay. Representative images and quantification of invasion assay by MDA-MB-231 cells (Scale bar, 100 μm) or A375 cells (Scale bar, 50 μm) in which Rab3D was depleted. ** p < 0.01, *** p < 0.001. (C). The effect of Rab3D on MMP-2 and MMP-9 activity. Gelatin zymography analysis of MMP-2 and MMP-9 activity in CM from Rab3D knockdown MDA-MB-231 cells or Rab3D overexpressing MCF-7 cells. (D). Representative images and quantification of migration assay by MCF-7 cells transfected to express Rab3D mutation. Scale bar, 200 μm. *** p < 0.001. (E). Representative images and quantification of the invasive phenotype. Scale bar, 100 μm. *** p < 0.001.

Journal: Oncotarget

Article Title: High expression of small GTPase Rab3D promotes cancer progression and metastasis

doi:

Figure Lengend Snippet: (A). Down-regulation of Rab3D markedly repressed tumor cells migration (wound healing assays). Representative images and quantification of migration assay in Rab3D knockdown MDA-MB-231 cells (Scale bar, 200 μm) or A375 cells (Scale bar, 50 μm). ** p < 0.01, *** p < 0.001. (B). Down-regulation of Rab3D inhibited the invasion capability of tumor cells on Matrigel-coated transwell insets in the invasion assay. Representative images and quantification of invasion assay by MDA-MB-231 cells (Scale bar, 100 μm) or A375 cells (Scale bar, 50 μm) in which Rab3D was depleted. ** p < 0.01, *** p < 0.001. (C). The effect of Rab3D on MMP-2 and MMP-9 activity. Gelatin zymography analysis of MMP-2 and MMP-9 activity in CM from Rab3D knockdown MDA-MB-231 cells or Rab3D overexpressing MCF-7 cells. (D). Representative images and quantification of migration assay by MCF-7 cells transfected to express Rab3D mutation. Scale bar, 200 μm. *** p < 0.001. (E). Representative images and quantification of the invasive phenotype. Scale bar, 100 μm. *** p < 0.001.

Article Snippet: The siRNAs for Rab3D were purchased from GenePharma.

Techniques: Migration, Knockdown, Invasion Assay, Activity Assay, Zymography, Transfection, Mutagenesis

(A). Western Blot analysis in Rab3D MCF-7 cells of EMT marker (E-cadherin and N-cadherin). (B). Measurement of E-cadherin or N-cadherin expression in siRab3D MDA-MB-231 cells. (C). The EMT-related signaling activation (AKT/GSK3β/Snail) in different group.

Journal: Oncotarget

Article Title: High expression of small GTPase Rab3D promotes cancer progression and metastasis

doi:

Figure Lengend Snippet: (A). Western Blot analysis in Rab3D MCF-7 cells of EMT marker (E-cadherin and N-cadherin). (B). Measurement of E-cadherin or N-cadherin expression in siRab3D MDA-MB-231 cells. (C). The EMT-related signaling activation (AKT/GSK3β/Snail) in different group.

Article Snippet: The siRNAs for Rab3D were purchased from GenePharma.

Techniques: Western Blot, Marker, Expressing, Activation Assay

(A). Identification and characterization of exosomes. Exosomes were isolated by sequential centrifugations from supernatants. Scale bar, 100 nm. An inset panel shows the exosomal marker, tetraspanin protein CD63 and Alix by Western Blot. (B). The size distribution of exosomes was analyzed by DLS and given as average ± standard deviation (n = 3). (C). Representative images and quantification of exosomes. Scale bar, 200 nm. *** p < 0.001. (D). The total protein level of extracellular exosomes was detected by BCA (n = 3). (E). Western Blot analysis of exosomal marker CD63 and Alix in exosomes from Rab3D-MCF-7 cells or siRab3D-MDA-MB-231 cells. (F) The level of secreted Hsp90α was detected by ELISA assay when the MCF-7 cells were transfected with different plasmid. (G). Quantification of migration assay of recombinant Hsp90α treated MDA-MB-231 transfected with scramble RNA or Rab3D siRNA. Statistically significant p values are indicated. ** p < 0.01, *** p < 0.001. (H). Measurement of invasion in siRab3D MDA-MB-231 with or without addition of recombinant Hsp90α. * p < 0.05, ** p < 0.01, *** p < 0.001. (I). Quantification of migration assay. MCF-7 cells that expressed Rab3D, with or without Hsp90α neutralizing antibody, were seeded. The relative migration distance was calculated after 16 h. * p < 0.05, ** p < 0.01, *** p < 0.001. (J). Quantification of matrigel invasion assay. The effect of blocking extracellular Hsp90α in MCF-7 cells over-expressing Rab3D on invasive ability. ** p < 0.01, *** p < 0.001.

Journal: Oncotarget

Article Title: High expression of small GTPase Rab3D promotes cancer progression and metastasis

doi:

Figure Lengend Snippet: (A). Identification and characterization of exosomes. Exosomes were isolated by sequential centrifugations from supernatants. Scale bar, 100 nm. An inset panel shows the exosomal marker, tetraspanin protein CD63 and Alix by Western Blot. (B). The size distribution of exosomes was analyzed by DLS and given as average ± standard deviation (n = 3). (C). Representative images and quantification of exosomes. Scale bar, 200 nm. *** p < 0.001. (D). The total protein level of extracellular exosomes was detected by BCA (n = 3). (E). Western Blot analysis of exosomal marker CD63 and Alix in exosomes from Rab3D-MCF-7 cells or siRab3D-MDA-MB-231 cells. (F) The level of secreted Hsp90α was detected by ELISA assay when the MCF-7 cells were transfected with different plasmid. (G). Quantification of migration assay of recombinant Hsp90α treated MDA-MB-231 transfected with scramble RNA or Rab3D siRNA. Statistically significant p values are indicated. ** p < 0.01, *** p < 0.001. (H). Measurement of invasion in siRab3D MDA-MB-231 with or without addition of recombinant Hsp90α. * p < 0.05, ** p < 0.01, *** p < 0.001. (I). Quantification of migration assay. MCF-7 cells that expressed Rab3D, with or without Hsp90α neutralizing antibody, were seeded. The relative migration distance was calculated after 16 h. * p < 0.05, ** p < 0.01, *** p < 0.001. (J). Quantification of matrigel invasion assay. The effect of blocking extracellular Hsp90α in MCF-7 cells over-expressing Rab3D on invasive ability. ** p < 0.01, *** p < 0.001.

Article Snippet: The siRNAs for Rab3D were purchased from GenePharma.

Techniques: Isolation, Marker, Western Blot, Standard Deviation, Enzyme-linked Immunosorbent Assay, Transfection, Plasmid Preparation, Migration, Recombinant, Invasion Assay, Blocking Assay, Expressing

(A-B). Rab3D expression in stably transfected tumor cell lines. (C). Representative images of primary tumors and lung section stained with hematoxilin and eosin in control and Rab3D-MCF-7 xenografts bearing mice (n = 5 mice per group). (D). H & E staining of lung in control and shRab3D-MDA-MB-231 xenografts bearing mice. (E). Immunohistochemical staining images and quantification of EMT-related signaling activation in control and Rab3D-MCF-7 xenografts. Scale bar, 50μm. (F). The level of plasma Hsp90α in nude mice detected by ELISA assay (n = 5 mice per group). (G). The working model for Rab3D-induced tumor cell invasion. In response to hypoxia, intracellular Rab3D is increased and its expression is correlated with tumor malignancy. Rab3D regulates exosomes release and Hsp90α secretion, which promotes EMT and tumor metastasis. eHsp90α indicates extracellular Hsp90α.

Journal: Oncotarget

Article Title: High expression of small GTPase Rab3D promotes cancer progression and metastasis

doi:

Figure Lengend Snippet: (A-B). Rab3D expression in stably transfected tumor cell lines. (C). Representative images of primary tumors and lung section stained with hematoxilin and eosin in control and Rab3D-MCF-7 xenografts bearing mice (n = 5 mice per group). (D). H & E staining of lung in control and shRab3D-MDA-MB-231 xenografts bearing mice. (E). Immunohistochemical staining images and quantification of EMT-related signaling activation in control and Rab3D-MCF-7 xenografts. Scale bar, 50μm. (F). The level of plasma Hsp90α in nude mice detected by ELISA assay (n = 5 mice per group). (G). The working model for Rab3D-induced tumor cell invasion. In response to hypoxia, intracellular Rab3D is increased and its expression is correlated with tumor malignancy. Rab3D regulates exosomes release and Hsp90α secretion, which promotes EMT and tumor metastasis. eHsp90α indicates extracellular Hsp90α.

Article Snippet: The siRNAs for Rab3D were purchased from GenePharma.

Techniques: Expressing, Stable Transfection, Transfection, Staining, Control, Immunohistochemical staining, Activation Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

a , Crossing gene expression microarrays of A673 EwS cells, harboring a DOX-inducible shRNA against EWSR1-FLI1 (A673/TR/shEF1) profiled with/without addition of DOX, with 166 transcriptomes of primary EwS tumors with matched clinical annotation, reveals MYBL2 as the top EWSR1-FLI regulated gene associated with poor patient outcome. b , Kaplan-Meier plot of overall survival in a cohort of 166 primary EwS patients for which Affymetrix gene expression data and clinical annotations were available. Patients were stratified by quintile MYBL2 expression. Mantel-Haenszel-Test. c , Western blot using antibodies against EWSR1-FLI1 and MYBL2 in A673/TR/shEF1 cells. EWSR1-FLI1 was knocked down for 7 days by DOX-treatment and re-expressed by removing DOX from the media for 10 days. β-actin served as loading control. d , Epigenetic profile of the MYBL2 locus inA673 and SK-N-MC EwS cells. Signals from published DNAse-Seq data (DNAse I hypersensitivity; HS) and ChIP-seq data for EWSR1-FLI1, H3K4me1 and H3K27ac in EwS cells transfected with either a control shRNA (shGFP) or a specific shRNA against EWSR1-FLI1 (shEF1) are displayed. e , Luciferase reporter assay after cloning haplotypes of the MYBL2-associated GGAA-microsatellite (mSat) from different cell lines into a pGL3 expression vector. The vectors were transfected in A673/TR/shEF1 cells, which were treated either with or without DOX. Data are mean and SEM, n=4. Unpaired student’s t-test. f , Analysis of relative MYBL2 expression in RDES EwS cells after CRISPRi-mediated blockage of protein binding to the MYBL2-associated GGAA-microsatellite. Data are mean and SEM, n =4. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: a , Crossing gene expression microarrays of A673 EwS cells, harboring a DOX-inducible shRNA against EWSR1-FLI1 (A673/TR/shEF1) profiled with/without addition of DOX, with 166 transcriptomes of primary EwS tumors with matched clinical annotation, reveals MYBL2 as the top EWSR1-FLI regulated gene associated with poor patient outcome. b , Kaplan-Meier plot of overall survival in a cohort of 166 primary EwS patients for which Affymetrix gene expression data and clinical annotations were available. Patients were stratified by quintile MYBL2 expression. Mantel-Haenszel-Test. c , Western blot using antibodies against EWSR1-FLI1 and MYBL2 in A673/TR/shEF1 cells. EWSR1-FLI1 was knocked down for 7 days by DOX-treatment and re-expressed by removing DOX from the media for 10 days. β-actin served as loading control. d , Epigenetic profile of the MYBL2 locus inA673 and SK-N-MC EwS cells. Signals from published DNAse-Seq data (DNAse I hypersensitivity; HS) and ChIP-seq data for EWSR1-FLI1, H3K4me1 and H3K27ac in EwS cells transfected with either a control shRNA (shGFP) or a specific shRNA against EWSR1-FLI1 (shEF1) are displayed. e , Luciferase reporter assay after cloning haplotypes of the MYBL2-associated GGAA-microsatellite (mSat) from different cell lines into a pGL3 expression vector. The vectors were transfected in A673/TR/shEF1 cells, which were treated either with or without DOX. Data are mean and SEM, n=4. Unpaired student’s t-test. f , Analysis of relative MYBL2 expression in RDES EwS cells after CRISPRi-mediated blockage of protein binding to the MYBL2-associated GGAA-microsatellite. Data are mean and SEM, n =4. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: Expressing, shRNA, Western Blot, ChIP-sequencing, Transfection, Luciferase, Reporter Assay, Clone Assay, Plasmid Preparation, Protein Binding

a , EWSR1-FLI1, MYBL2, GAPDH and B2M expression in A673/TR/shEF1 cells containing a DOX-inducible specific shRNA construct against EWSR1-FLI1, measured by Affymetrix HG-U133A2.0 arrays (GSE27524) at different time points after start of DOX addition to the media. b , Ex vivo analysis of EWSR1-FLI1 and MYBL2 expression by qRT-PCR in A673/TR/shEF1 xenografts either with or without addition of DOX to the drinking water. n=5 mice per group. Unpaired student’s t-test. c , Representative pictures of IHC p-MYBL2 staining of A673/TR/shEF1 xenografts in NSG mice either with or without addition of DOX to the drinking water. Scale bar is 50 μm. d , EWSR1-FLI1 and MYBL2 expression as measured by qRT-PCR in ten EwS cell lines containing a DOX-inducible specific shRNA construct directed against EWSR1-FLI1 either with or without addition of DOX. e,f Ranked log2 MYBL2 expression intensities in 166 primary EwS tumors as determined by Affymetrix gene expression microarrays (e) and representative images of IHC staining for p-MYBL2 of a TMA comprising 208 primary EwS tumors (f). Scale bar is 50 μm. Percentages of patients showing either low, intermediate, strong or very strong MYBL2 expression are reported. g , Linear regression of FLI1 expression onto MYBL2 expression in an Affymetrix gene expression dataset comprising 32 primary EwS tumors with EWSR1-FLI1 translocation. FLI1 expression was used as a surrogate for EWSR1-FLI1 expression, as wildtype FLI1 is not expressed in EwS. h , MYBL2 expression as determined by RNA-seq depending on the number of consecutive GGAA-repeats (lead/longer allele) of the MYBL2-associated GGAA-microsatellite in 13 primary EwS for which matched whole genome sequencing data was available. i , Analysis of relative EWSR1-FLI1 expression in RDES EwS cells after CRISPRi-mediated inhibition of the MYBL2-associated GGAA-microsatellite. Data are mean and SEM, n=2. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: a , EWSR1-FLI1, MYBL2, GAPDH and B2M expression in A673/TR/shEF1 cells containing a DOX-inducible specific shRNA construct against EWSR1-FLI1, measured by Affymetrix HG-U133A2.0 arrays (GSE27524) at different time points after start of DOX addition to the media. b , Ex vivo analysis of EWSR1-FLI1 and MYBL2 expression by qRT-PCR in A673/TR/shEF1 xenografts either with or without addition of DOX to the drinking water. n=5 mice per group. Unpaired student’s t-test. c , Representative pictures of IHC p-MYBL2 staining of A673/TR/shEF1 xenografts in NSG mice either with or without addition of DOX to the drinking water. Scale bar is 50 μm. d , EWSR1-FLI1 and MYBL2 expression as measured by qRT-PCR in ten EwS cell lines containing a DOX-inducible specific shRNA construct directed against EWSR1-FLI1 either with or without addition of DOX. e,f Ranked log2 MYBL2 expression intensities in 166 primary EwS tumors as determined by Affymetrix gene expression microarrays (e) and representative images of IHC staining for p-MYBL2 of a TMA comprising 208 primary EwS tumors (f). Scale bar is 50 μm. Percentages of patients showing either low, intermediate, strong or very strong MYBL2 expression are reported. g , Linear regression of FLI1 expression onto MYBL2 expression in an Affymetrix gene expression dataset comprising 32 primary EwS tumors with EWSR1-FLI1 translocation. FLI1 expression was used as a surrogate for EWSR1-FLI1 expression, as wildtype FLI1 is not expressed in EwS. h , MYBL2 expression as determined by RNA-seq depending on the number of consecutive GGAA-repeats (lead/longer allele) of the MYBL2-associated GGAA-microsatellite in 13 primary EwS for which matched whole genome sequencing data was available. i , Analysis of relative EWSR1-FLI1 expression in RDES EwS cells after CRISPRi-mediated inhibition of the MYBL2-associated GGAA-microsatellite. Data are mean and SEM, n=2. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: Expressing, shRNA, Construct, Ex Vivo, Quantitative RT-PCR, Paraffin-embedded Immunohistochemistry, Staining, Immunohistochemistry, Translocation Assay, RNA Sequencing Assay, Sequencing, Inhibition

a , Heat-map showing genes whose expression is positively or negatively correlated with MYBL2 expression in Affymetrix gene expression data of 166 primary EwS tumors. GSEA of the same dataset showing selected gene sets enriched in MYBL2 high-expressing tumors, which comprised MYBL2 targets , proliferation , cell cycle progression and sensitization to apoptosis mediated by a CDK-inhibiting protein . b , Viable cell count 96h after transfection of three different EwS cell lines with either four different specific siRNAs directed against MYBL2 (summary of four different siRNAs shown) or a non-targeting siControl. Data are mean and SEM, n ≥3. Unpaired student’s t-test. c , Analysis of cell cycle phases and cell death (sub G1/G0) 96h after transfection with either four different specific siRNAs directed against MYBL2 (summary of four different siRNAs shown) or a nontargeting siControl, using Propidium-Iodide staining and flow cytometry. Data are mean and SEM, n=3. Unpaired student’s t-test. d , Analysis of apoptosis in three different EwS cell lines 96h after transfection with either four different specific siRNAs directed against MYBL2 (summary of four different siRNAs shown) or a non-targeting siControl, using annexin V/propidium-iodide staining and flow cytometry. Data are mean and SEM, n=3. Unpaired student’s t-test. e , Representative colony forming assays (CFAs) of A673 and SK-N-MC cells containing either DOX-inducible specific shRNA constructs directed against MYBL2 or a non-targeting shControl. Cells were grown either with or without DOX. Colonies were stained with Crystal-violet 10–14 days after seeding. f,g , Kaplan-Meier plots showing survival time of NSG mice xenografted with A673 or SK-N-MC cells, containing either DOX-inducible specific shMYBL2 or non-targeting shControl constructs. Once tumors were palpable, mice were randomized and treated with either vehicle (−) or DOX (+). Mantel-Haenszel-Test. h , Representative micrographs of HE and IHC staining for cleaved caspase 3 (CC3) of NSG mice xenografted with A673 or SK-N-MC cells containing a DOX-inducible specific shMYBL2 Mice were treated with either vehicle (−) or DOX (+). Scale bar is 50 μm. i , Quantification of cells arrested in M-phase and automated quantification of the picture area positive for CC3 of xenografts from A673 or SK-N-MC cells containing a DOX-inducible specific shMYBL2. Mice were treated with either vehicle (−) or DOX (+). Data are mean and SEM of ten high-power fields in five tumors for each condition. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: a , Heat-map showing genes whose expression is positively or negatively correlated with MYBL2 expression in Affymetrix gene expression data of 166 primary EwS tumors. GSEA of the same dataset showing selected gene sets enriched in MYBL2 high-expressing tumors, which comprised MYBL2 targets , proliferation , cell cycle progression and sensitization to apoptosis mediated by a CDK-inhibiting protein . b , Viable cell count 96h after transfection of three different EwS cell lines with either four different specific siRNAs directed against MYBL2 (summary of four different siRNAs shown) or a non-targeting siControl. Data are mean and SEM, n ≥3. Unpaired student’s t-test. c , Analysis of cell cycle phases and cell death (sub G1/G0) 96h after transfection with either four different specific siRNAs directed against MYBL2 (summary of four different siRNAs shown) or a nontargeting siControl, using Propidium-Iodide staining and flow cytometry. Data are mean and SEM, n=3. Unpaired student’s t-test. d , Analysis of apoptosis in three different EwS cell lines 96h after transfection with either four different specific siRNAs directed against MYBL2 (summary of four different siRNAs shown) or a non-targeting siControl, using annexin V/propidium-iodide staining and flow cytometry. Data are mean and SEM, n=3. Unpaired student’s t-test. e , Representative colony forming assays (CFAs) of A673 and SK-N-MC cells containing either DOX-inducible specific shRNA constructs directed against MYBL2 or a non-targeting shControl. Cells were grown either with or without DOX. Colonies were stained with Crystal-violet 10–14 days after seeding. f,g , Kaplan-Meier plots showing survival time of NSG mice xenografted with A673 or SK-N-MC cells, containing either DOX-inducible specific shMYBL2 or non-targeting shControl constructs. Once tumors were palpable, mice were randomized and treated with either vehicle (−) or DOX (+). Mantel-Haenszel-Test. h , Representative micrographs of HE and IHC staining for cleaved caspase 3 (CC3) of NSG mice xenografted with A673 or SK-N-MC cells containing a DOX-inducible specific shMYBL2 Mice were treated with either vehicle (−) or DOX (+). Scale bar is 50 μm. i , Quantification of cells arrested in M-phase and automated quantification of the picture area positive for CC3 of xenografts from A673 or SK-N-MC cells containing a DOX-inducible specific shMYBL2. Mice were treated with either vehicle (−) or DOX (+). Data are mean and SEM of ten high-power fields in five tumors for each condition. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: Expressing, Cell Counting, Transfection, Staining, Flow Cytometry, shRNA, Construct, Immunohistochemistry

a , MYBL2 expression in 24 EwS cell lines, normalized to expression in A673 as measured by qRT-PCR. b , Relative MYBL2 expression as measured by qRT-PCR after transfection of A673, SK-N-MC and RDES EwS cell lines with either four different specific siRNAs directed against MYBL2 or a non-targeting siControl. Data are mean and SEM, n ≥3. Unpaired student’s t-test. c , Summary of four different specific siRNAs directed against MYBL2 shown in (b). Data are mean and SEM, n ≥3. Unpaired student’s t-test. d , Relative MYBL2 expression as measured by qRT-PCR of A673 and SK-N-MC cells containing either DOX-inducible specific shRNA constructs directed against MYBL2 or a non-targeting shControl. Cells were grown either with or without DOX. n =3. Unpaired students t-test. e , Relative colony number of CFAs of A673 and SK-N-MC cells containing either DOX-inducible specific shRNA constructs directed against MYBL2 or a non-targeting shControl. Cells were grown either with or without DOX. n =3. Unpaired students t-test. f , Representative images of NSG mice xenografts of A673 and SK-N-MC cells containing a DOX-inducible specific shRNA constructs directed against MYBL2 stained for p-MYBL2. Scale bar is 50 μm. Mice were treated either with or without addition of DOX to the drinking water. g , Quantification of p-MYBL2 staining as described in (f). Data are represented as mean and SEM of ten high-power fields in five tumors for each condition. Unpaired students t-test. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: a , MYBL2 expression in 24 EwS cell lines, normalized to expression in A673 as measured by qRT-PCR. b , Relative MYBL2 expression as measured by qRT-PCR after transfection of A673, SK-N-MC and RDES EwS cell lines with either four different specific siRNAs directed against MYBL2 or a non-targeting siControl. Data are mean and SEM, n ≥3. Unpaired student’s t-test. c , Summary of four different specific siRNAs directed against MYBL2 shown in (b). Data are mean and SEM, n ≥3. Unpaired student’s t-test. d , Relative MYBL2 expression as measured by qRT-PCR of A673 and SK-N-MC cells containing either DOX-inducible specific shRNA constructs directed against MYBL2 or a non-targeting shControl. Cells were grown either with or without DOX. n =3. Unpaired students t-test. e , Relative colony number of CFAs of A673 and SK-N-MC cells containing either DOX-inducible specific shRNA constructs directed against MYBL2 or a non-targeting shControl. Cells were grown either with or without DOX. n =3. Unpaired students t-test. f , Representative images of NSG mice xenografts of A673 and SK-N-MC cells containing a DOX-inducible specific shRNA constructs directed against MYBL2 stained for p-MYBL2. Scale bar is 50 μm. Mice were treated either with or without addition of DOX to the drinking water. g , Quantification of p-MYBL2 staining as described in (f). Data are represented as mean and SEM of ten high-power fields in five tumors for each condition. Unpaired students t-test. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: Expressing, Quantitative RT-PCR, Transfection, shRNA, Construct, Staining

Analysis of RNA-seq data showing differentially expressed genes (DEGs) after siRNA-mediated MYBL2 knockdown compared to a non-targeting siControl. A summary of three cell lines is shown; n =3 biological replicates per group per cell line. b , GSEA of RNA-seq data shown in (a). Displayed are 275 downregulated gene sets that had an FDR q<0.05. c , Analysis of MYBL2 ChIP-seq data from A673 cells shows MYBL2 peaks in the promoter regions of CCNF, BIRC5 and AURKB. Publicly available EWSR1-FLI1 ChIP-seq data from A673 cells was analyzed to exclude a direct regulation by EWSR1-FLI1 of these three genes. Whole cell extract (WCE) served as a control. d , Linear regression of CCNF , BIRC5 or AURKB expression onto MYBL2 expression in an Affymetrix gene expression dataset of 166 primary EwS tumors. e , Analysis of overall patient survival in a cohort of 166 primary EwS patients for which Affymetrix gene expression data and clinical annotations were available. Patients were stratified by median expression levels of the indicated gene. Mantel-Haenszel-Test. f , Viable cell count 96h after transfection of A673 and SK-N-MC cell lines with two different siRNA directed against either CCNF, BIRC5, AURKB (summary of two different siRNAs shown) or a non-targeting siControl. Data are mean and SEM, n=3. Unpaired student’s t-test. g , Cell death as measured by trypan blue positivity 96h after transfection of A673 and SK-N-MC EwS cells with two different siRNA directed against either CCNF, BIRC5, AURKB (summary of two different siRNAs shown) or a non-targeting siControl. Data are mean and SEM, n =3. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: Analysis of RNA-seq data showing differentially expressed genes (DEGs) after siRNA-mediated MYBL2 knockdown compared to a non-targeting siControl. A summary of three cell lines is shown; n =3 biological replicates per group per cell line. b , GSEA of RNA-seq data shown in (a). Displayed are 275 downregulated gene sets that had an FDR q<0.05. c , Analysis of MYBL2 ChIP-seq data from A673 cells shows MYBL2 peaks in the promoter regions of CCNF, BIRC5 and AURKB. Publicly available EWSR1-FLI1 ChIP-seq data from A673 cells was analyzed to exclude a direct regulation by EWSR1-FLI1 of these three genes. Whole cell extract (WCE) served as a control. d , Linear regression of CCNF , BIRC5 or AURKB expression onto MYBL2 expression in an Affymetrix gene expression dataset of 166 primary EwS tumors. e , Analysis of overall patient survival in a cohort of 166 primary EwS patients for which Affymetrix gene expression data and clinical annotations were available. Patients were stratified by median expression levels of the indicated gene. Mantel-Haenszel-Test. f , Viable cell count 96h after transfection of A673 and SK-N-MC cell lines with two different siRNA directed against either CCNF, BIRC5, AURKB (summary of two different siRNAs shown) or a non-targeting siControl. Data are mean and SEM, n=3. Unpaired student’s t-test. g , Cell death as measured by trypan blue positivity 96h after transfection of A673 and SK-N-MC EwS cells with two different siRNA directed against either CCNF, BIRC5, AURKB (summary of two different siRNAs shown) or a non-targeting siControl. Data are mean and SEM, n =3. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: RNA Sequencing Assay, ChIP-sequencing, Expressing, Cell Counting, Transfection

a , Selected negatively enriched gene sets in RNA-seq data after siRNA-mediated MYBL2 knockdown compared to a non-targeting siControl (summary of three cell lines, n =3). b , Flow-chart showing the algorithm used to identify the top functionally relevant downstream target genes of MYBL2. c , Validation of downregulation of selected DEGs by qRT-PCR after MYBL2 knockdown in SK-N-MC EwS cells, n=3. Unpaired student’s t-test. d , Relative gene expression of CCNF, BIRC5 and AURKB expression as measured by qRT-PCR after transfection of A673 and SK-N-MC EwS cell lines with either two different specific siRNAs directed against CCNF, BIRC5 or AURKB (summary of two siRNAs is shown) or a non-targeting siControl. Data are mean and SEM, n=3. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: a , Selected negatively enriched gene sets in RNA-seq data after siRNA-mediated MYBL2 knockdown compared to a non-targeting siControl (summary of three cell lines, n =3). b , Flow-chart showing the algorithm used to identify the top functionally relevant downstream target genes of MYBL2. c , Validation of downregulation of selected DEGs by qRT-PCR after MYBL2 knockdown in SK-N-MC EwS cells, n=3. Unpaired student’s t-test. d , Relative gene expression of CCNF, BIRC5 and AURKB expression as measured by qRT-PCR after transfection of A673 and SK-N-MC EwS cell lines with either two different specific siRNAs directed against CCNF, BIRC5 or AURKB (summary of two siRNAs is shown) or a non-targeting siControl. Data are mean and SEM, n=3. Unpaired student’s t-test. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: RNA Sequencing Assay, Quantitative RT-PCR, Expressing, Transfection

A673 cells containing either DOX-inducible specific shMYBL2 or non-targeting shControl constructs were treated with the CDK2 inhibitors CVT-313 or NU6140 at different concentrations. Additionally, cells were treated either with or without DOX. Relative cell viability was assessed by a Resazurin assay. Data are mean and SEM, n≥3. Unpaired student’s t-test. b , Left: Schematic of the experimental setting of CDK2 inhibitor treatment (NU6140) in vivo and tumor volume curves of NSG mice xenografted with A673 cells containing a DOX-inducible shMYBL2 construct, treated with/without DOX and either vehicle or NU6140 in a dose of 20 mg/kg or 40 mg/kg. Right: Mice were randomized to the treatment groups as soon as tumors were palpable. For each condition the mean tumor volume and SEM of 3–6 mice is shown. Unpaired student’s t-test. c , Representative micrographs of IHC staining for p-MYBL2 of NSG mice xenografted with A673/TR/shMYBL2 cells without DOX, but treatment with either vehicle or CDK2 inhibitor at a dose of 20 mg/kg or 40 mg/kg. Scale bar is 50 μm. d , Model of EWSR1-FLI1-dependent regulation of MYBL2 in EwS and its functional and therapeutic implications. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: A673 cells containing either DOX-inducible specific shMYBL2 or non-targeting shControl constructs were treated with the CDK2 inhibitors CVT-313 or NU6140 at different concentrations. Additionally, cells were treated either with or without DOX. Relative cell viability was assessed by a Resazurin assay. Data are mean and SEM, n≥3. Unpaired student’s t-test. b , Left: Schematic of the experimental setting of CDK2 inhibitor treatment (NU6140) in vivo and tumor volume curves of NSG mice xenografted with A673 cells containing a DOX-inducible shMYBL2 construct, treated with/without DOX and either vehicle or NU6140 in a dose of 20 mg/kg or 40 mg/kg. Right: Mice were randomized to the treatment groups as soon as tumors were palpable. For each condition the mean tumor volume and SEM of 3–6 mice is shown. Unpaired student’s t-test. c , Representative micrographs of IHC staining for p-MYBL2 of NSG mice xenografted with A673/TR/shMYBL2 cells without DOX, but treatment with either vehicle or CDK2 inhibitor at a dose of 20 mg/kg or 40 mg/kg. Scale bar is 50 μm. d , Model of EWSR1-FLI1-dependent regulation of MYBL2 in EwS and its functional and therapeutic implications. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: Construct, Resazurin Assay, In Vivo, Immunohistochemistry, Functional Assay

a , Relative MYBL2 expression as measured by qRT-PCR of RDES, SK-N-MC and EW16 Ewing sarcoma cell lines. Data are mean and SEM, n =3. Unpaired student’s t-test. b , MYBL2 high expressing cell lines (RDES, SK-N-MC) and a MYBL2 low expressing cell line (EW16) cells were treated with the CDK2 Inhibitor NU6140 in different concentrations. Relative cell growth was assessed by Resazurin assay. Data are mean and SEM, n =3. Unpaired student’s t-test. c , Fold change (FC) of mouse weight before and after treatment with up to 40 mg/kg of the CDK2 inhibitor NU6140 for 12 days. *** P <0.001, ** P <0.01, * P <0.05.

Journal: bioRxiv

Article Title: Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

doi: 10.1101/506659

Figure Lengend Snippet: a , Relative MYBL2 expression as measured by qRT-PCR of RDES, SK-N-MC and EW16 Ewing sarcoma cell lines. Data are mean and SEM, n =3. Unpaired student’s t-test. b , MYBL2 high expressing cell lines (RDES, SK-N-MC) and a MYBL2 low expressing cell line (EW16) cells were treated with the CDK2 Inhibitor NU6140 in different concentrations. Relative cell growth was assessed by Resazurin assay. Data are mean and SEM, n =3. Unpaired student’s t-test. c , Fold change (FC) of mouse weight before and after treatment with up to 40 mg/kg of the CDK2 inhibitor NU6140 for 12 days. *** P <0.001, ** P <0.01, * P <0.05.

Article Snippet: Either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting MYBL2 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system .

Techniques: Expressing, Quantitative RT-PCR, Resazurin Assay

Expression pattern of POU1F1 in stem cell‐like cells of GC. (A) Analysis of the capacity of self‐renewal among PAMC‐82, SNU16 parental cells, and spheroids. (B and C) Expression levels of stem cell markers including CD44, Oct4, Sox2, and Nanog in PAMC‐82 and SNU‐16 cells, as well as their spheroids were detected using qRT‐PCR and western blotting analysis, respectively. (D) Western blotting was performed to validate the expression levels of stem cell marker, Sox4. (E and F) Expression status of POU1F1 mRNA and protein was determined using qRT‐PCR and western blotting assays among PAMC‐82 and SNU‐16 parental cells, compared with their spheroids, respectively. β‐Actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: Expression pattern of POU1F1 in stem cell‐like cells of GC. (A) Analysis of the capacity of self‐renewal among PAMC‐82, SNU16 parental cells, and spheroids. (B and C) Expression levels of stem cell markers including CD44, Oct4, Sox2, and Nanog in PAMC‐82 and SNU‐16 cells, as well as their spheroids were detected using qRT‐PCR and western blotting analysis, respectively. (D) Western blotting was performed to validate the expression levels of stem cell marker, Sox4. (E and F) Expression status of POU1F1 mRNA and protein was determined using qRT‐PCR and western blotting assays among PAMC‐82 and SNU‐16 parental cells, compared with their spheroids, respectively. β‐Actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Marker, Control

Biological functions of POU1F1 knockdown or overexpression on the stem‐like characteristics of GC. As for gain or loss‐of‐function, PAMC‐82 cells were transfected with POU1F1 overexpressing vector, and SNU‐16 cells were transfected with si‐POU1F1, as well as their negative controls. (A–C) qRT‐PCR and western blotting analysis were employed to assess the transfection efficiency. (D) Analysis of the capacity of self‐renewal among PAMC‐82 and SNU‐16 cells stably overexpressing POU1F1 or silencing POU1F1. (E and F) The mRNA and protein levels of stem cell markers, including CD44, Oct4, Sox2, and Nanog, were determined by qRT‐PCR and western blotting. (G) Western blotting was performed to validate the expression levels of stem cell marker, Sox4. β‐Actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: Biological functions of POU1F1 knockdown or overexpression on the stem‐like characteristics of GC. As for gain or loss‐of‐function, PAMC‐82 cells were transfected with POU1F1 overexpressing vector, and SNU‐16 cells were transfected with si‐POU1F1, as well as their negative controls. (A–C) qRT‐PCR and western blotting analysis were employed to assess the transfection efficiency. (D) Analysis of the capacity of self‐renewal among PAMC‐82 and SNU‐16 cells stably overexpressing POU1F1 or silencing POU1F1. (E and F) The mRNA and protein levels of stem cell markers, including CD44, Oct4, Sox2, and Nanog, were determined by qRT‐PCR and western blotting. (G) Western blotting was performed to validate the expression levels of stem cell marker, Sox4. β‐Actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques: Knockdown, Over Expression, Transfection, Plasmid Preparation, Quantitative RT-PCR, Western Blot, Stable Transfection, Expressing, Marker, Control

Regulation of POU1F1 on the characteristics associated with stemness in GC. (A and B) CCK‐8 assay was subjected to validate the cell viability in stable PAMC‐82 and SNU‐16 cells within the exposure of indicated concentrations of cisplatin for 72 h. (C and D) Transwell system for assessing cell migration and invasion was performed in PAMC‐82 and SNU‐16 cells stably overexpressing POU1F1 or silencing POU1F1, respectively. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: Regulation of POU1F1 on the characteristics associated with stemness in GC. (A and B) CCK‐8 assay was subjected to validate the cell viability in stable PAMC‐82 and SNU‐16 cells within the exposure of indicated concentrations of cisplatin for 72 h. (C and D) Transwell system for assessing cell migration and invasion was performed in PAMC‐82 and SNU‐16 cells stably overexpressing POU1F1 or silencing POU1F1, respectively. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques: CCK-8 Assay, Migration, Stable Transfection

POU1F1 increases the stemness of GC cells through glycolysis reprogramming. (A and B) PAMC‐82 and SNU16 cells stably overexpressing POU1F1 or silencing POU1F1 were cultured for 36 h, then the levels of glucose consumption and lactic acid production were measured on the basis the cell numbers. Fold changes were normalized (μmol/10 6 cells). (C and D) Extracellular acid ratio (ECAR) was measured by Seahorse XF in PAMC‐82 and SNU16 cells stably overexpressing POU1F1 or silencing POU1F1. ECAR curves from cells treated with glucose, oligomycin, and 2‐DG. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: POU1F1 increases the stemness of GC cells through glycolysis reprogramming. (A and B) PAMC‐82 and SNU16 cells stably overexpressing POU1F1 or silencing POU1F1 were cultured for 36 h, then the levels of glucose consumption and lactic acid production were measured on the basis the cell numbers. Fold changes were normalized (μmol/10 6 cells). (C and D) Extracellular acid ratio (ECAR) was measured by Seahorse XF in PAMC‐82 and SNU16 cells stably overexpressing POU1F1 or silencing POU1F1. ECAR curves from cells treated with glucose, oligomycin, and 2‐DG. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques: Stable Transfection, Cell Culture

The transcriptional regulation of POU1F1 on ENO1. (A) Online bioinformatics tool to predict the DNA‐binding sites for POU1F1 and the promoter of ENO1. (B) ChIP assay was performed in PAMC‐82 cells to explore the binding relationship between POU1F1 and the promoter region of ENO1. (C) Luciferase activity was measured using Luciferase reporter assay, in PAMC‐82 cells transfected with pGL3‐ENO1, with or without POU1F1 overexpression, as well as in SNU‐16 cells transfected with pGL3‐ENO1, with or without POU1F1 knockdown. (D) Levels of ENO1 mRNA were detected in PAMC‐82 cells with or without POU1F1 overexpression, as well as in SNU‐16 cells with or without POU1F1 knockdown. (E) The protein levels of POU1F1 were validated using western blot analysis, and β‐actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: The transcriptional regulation of POU1F1 on ENO1. (A) Online bioinformatics tool to predict the DNA‐binding sites for POU1F1 and the promoter of ENO1. (B) ChIP assay was performed in PAMC‐82 cells to explore the binding relationship between POU1F1 and the promoter region of ENO1. (C) Luciferase activity was measured using Luciferase reporter assay, in PAMC‐82 cells transfected with pGL3‐ENO1, with or without POU1F1 overexpression, as well as in SNU‐16 cells transfected with pGL3‐ENO1, with or without POU1F1 knockdown. (D) Levels of ENO1 mRNA were detected in PAMC‐82 cells with or without POU1F1 overexpression, as well as in SNU‐16 cells with or without POU1F1 knockdown. (E) The protein levels of POU1F1 were validated using western blot analysis, and β‐actin was normalized as a loading control. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques: Binding Assay, Luciferase, Activity Assay, Reporter Assay, Transfection, Over Expression, Knockdown, Western Blot, Control

ENO1 overexpression reverses POU1F1‐mediated glycolysis and stem‐like characteristics of GC cells. SNU‐16 cells with stably POU1F1 silencing were co‐transfected with ENO1 overexpressing plasmid or its empty vector. (A and B) qRT‐PCR and western blotting assays to assess the expression of ENO1 in the mRNA and protein levels. (C) The levels of glucose consumption and lactic acid production were tested according to the cell numbers. (D) The ability of self‐renewal was evaluated using sphere formation assay. (E and F) Transwell assay for assessing the cell migration and invasion. (G) Extracellular acid ratio (ECAR) was measured by Seahorse XF. ECAR curves from cells treated with glucose, oligomycin, and 2‐DG. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: ENO1 overexpression reverses POU1F1‐mediated glycolysis and stem‐like characteristics of GC cells. SNU‐16 cells with stably POU1F1 silencing were co‐transfected with ENO1 overexpressing plasmid or its empty vector. (A and B) qRT‐PCR and western blotting assays to assess the expression of ENO1 in the mRNA and protein levels. (C) The levels of glucose consumption and lactic acid production were tested according to the cell numbers. (D) The ability of self‐renewal was evaluated using sphere formation assay. (E and F) Transwell assay for assessing the cell migration and invasion. (G) Extracellular acid ratio (ECAR) was measured by Seahorse XF. ECAR curves from cells treated with glucose, oligomycin, and 2‐DG. Results were from representative experiments in triplicate and expressed as the mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques: Over Expression, Stable Transfection, Transfection, Plasmid Preparation, Quantitative RT-PCR, Western Blot, Expressing, Tube Formation Assay, Transwell Assay, Migration

A schematic graph for summarizing the role of POU1F1 in regulating stem‐like characteristics of GC by glycolysis reprogramming.

Journal: The Kaohsiung Journal of Medical Sciences

Article Title: Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1 ‐mediated glycolysis reprogramming

doi: 10.1002/kjm2.12720

Figure Lengend Snippet: A schematic graph for summarizing the role of POU1F1 in regulating stem‐like characteristics of GC by glycolysis reprogramming.

Article Snippet: For loss‐of‐function, lentiviral particles equipped with the corresponding short hairpin RNAs (shRNAs) specifically targeting POU1F1 were synthesized and purchased from GeneChem (Shanghai, China), which was then utilized for the following cell infection.

Techniques:

a Analysis of cell growth and cell death of A673 and RDES EwS cells with/without siRNA- or shRNA-mediated knockdown of CALCB . Left panel A673 and RDES: Given is the mean of relative cell count compared to Co (Control), which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs ( n = 3–5). SEM and unpaired two-tailed Student’s t test of relative total cell count. Right panel A673 and RDES: Knockdown of CALCB was verified by qRT-PCR. Given is the mean gene expression and SEM; unpaired two-tailed Student’s t test. b Colony-forming assays of A673 and RDES EwS cells with/without siRNA- or dox-induced shRNA-mediated knockdown of CALCB or RAMP1 . Mean colony number and SEM normalized to control, which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs ( n = 3–6). Unpaired two-tailed Student’s t test. Representative images of each condition are shown. Knockdown of CALCB and RAMP1 were verified by qRT-PCR and are displayed in Fig. 4a and Supplementary Fig. . c Sphere-formation assays of A673 and RDES EwS cells with/without dox-induced shRNA-mediated knockdown of CALCB and RAMP1 . Sphere index was calculated by addition of diameter of all existing spheres in one well divided by diameter of spheres in the control well. Mean and SEM ( n = 3–6); unpaired two-tailed Student’s t test. n.s. P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Journal: Cell Death & Disease

Article Title: Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma

doi: 10.1038/s41419-019-1372-0

Figure Lengend Snippet: a Analysis of cell growth and cell death of A673 and RDES EwS cells with/without siRNA- or shRNA-mediated knockdown of CALCB . Left panel A673 and RDES: Given is the mean of relative cell count compared to Co (Control), which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs ( n = 3–5). SEM and unpaired two-tailed Student’s t test of relative total cell count. Right panel A673 and RDES: Knockdown of CALCB was verified by qRT-PCR. Given is the mean gene expression and SEM; unpaired two-tailed Student’s t test. b Colony-forming assays of A673 and RDES EwS cells with/without siRNA- or dox-induced shRNA-mediated knockdown of CALCB or RAMP1 . Mean colony number and SEM normalized to control, which either received according doses of a non-targeting siControl or did not receive dox in assays with dox-inducible shRNAs ( n = 3–6). Unpaired two-tailed Student’s t test. Representative images of each condition are shown. Knockdown of CALCB and RAMP1 were verified by qRT-PCR and are displayed in Fig. 4a and Supplementary Fig. . c Sphere-formation assays of A673 and RDES EwS cells with/without dox-induced shRNA-mediated knockdown of CALCB and RAMP1 . Sphere index was calculated by addition of diameter of all existing spheres in one well divided by diameter of spheres in the control well. Mean and SEM ( n = 3–6); unpaired two-tailed Student’s t test. n.s. P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Article Snippet: For generation of EwS cell lines with dox-inducible constructs (here in A673 and RDES), either a non-targeting negative control shRNA (MWG Eurofins Genomics) or specific shRNAs targeting CALCB or RAMP1 (MWG Eurofins Genomics) were cloned in the pLKO-Tet-on-all-in-one system (Addgene plasmid # 21915, Cambridge, MA, USA) as described previously .

Techniques: shRNA, Cell Counting, Two Tailed Test, Quantitative RT-PCR, Expressing

Downregulated BMAL1 promoted p53 expression in T2DM. (A) Protein expression of BMAL1, p53 and p21 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs as determined by western blot. (B) qRT-PCR analysis of BMAL1, p53 and p21 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs. (C) Immunofluorescence staining of p53 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs. Scale bars: 100 µm. All data are mean±s.e.m. and representative of three independent experiments. n =3. β-actin was used as a loading control. Statistical significance was defined as * P <0.05; ** P <0.01.

Journal: Biology Open

Article Title: Downregulated brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 inhibits osteogenesis of BMSCs through p53 in type 2 diabetes mellitus

doi: 10.1242/bio.051482

Figure Lengend Snippet: Downregulated BMAL1 promoted p53 expression in T2DM. (A) Protein expression of BMAL1, p53 and p21 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs as determined by western blot. (B) qRT-PCR analysis of BMAL1, p53 and p21 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs. (C) Immunofluorescence staining of p53 in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs. Scale bars: 100 µm. All data are mean±s.e.m. and representative of three independent experiments. n =3. β-actin was used as a loading control. Statistical significance was defined as * P <0.05; ** P <0.01.

Article Snippet: The lentiviral vector carrying specific p53-targeting shRNA was obtained from GenePharma Co., Ltd. (Shanghai, China; Gene ID: 24842).

Techniques: Expressing, Western Blot, Quantitative RT-PCR, Immunofluorescence, Staining

Inhibition of osteogenic differentiation of BMSCs by BMAL1 downregulation in T2DM was mediated by p53. (A) Western blot analysis of BMAL1, Runx2, Alp, Osx and p53 expression in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs with or without 20 μM PFT-α treatment after 7 days of osteogenic differentiation. (B) The mRNA expression of Runx2, Osx and Alp in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs were determined by qRT-PCR, following 7 days of osteogenic differentiation, with or without 20 μM PFT-α treatment. (C) Osteogenic differentiation ability of WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs with or without 20 μM PFT-α treatment as determined by alkaline phosphatase activity after osteogenic differentiation for 7 days. Data are from five independent experiments and are expressed as mean±s.e.m.. n =5. Statistical significance was defined as * P <0.05; # P <0.03. n.s: not significant.

Journal: Biology Open

Article Title: Downregulated brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 inhibits osteogenesis of BMSCs through p53 in type 2 diabetes mellitus

doi: 10.1242/bio.051482

Figure Lengend Snippet: Inhibition of osteogenic differentiation of BMSCs by BMAL1 downregulation in T2DM was mediated by p53. (A) Western blot analysis of BMAL1, Runx2, Alp, Osx and p53 expression in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs with or without 20 μM PFT-α treatment after 7 days of osteogenic differentiation. (B) The mRNA expression of Runx2, Osx and Alp in WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs were determined by qRT-PCR, following 7 days of osteogenic differentiation, with or without 20 μM PFT-α treatment. (C) Osteogenic differentiation ability of WT Wistar BMSCs, diabetic GK BMSCs and GK-BMAL1 BMSCs with or without 20 μM PFT-α treatment as determined by alkaline phosphatase activity after osteogenic differentiation for 7 days. Data are from five independent experiments and are expressed as mean±s.e.m.. n =5. Statistical significance was defined as * P <0.05; # P <0.03. n.s: not significant.

Article Snippet: The lentiviral vector carrying specific p53-targeting shRNA was obtained from GenePharma Co., Ltd. (Shanghai, China; Gene ID: 24842).

Techniques: Inhibition, Western Blot, Expressing, Quantitative RT-PCR, Activity Assay

KRT17 expression levels in PAC tissue samples. (A) Quantitative PCR results demonstrated significantly increased expression levels of KRT17 mRNA in PAC tissues compared with adjacent normal tissues. n=18. (B) Bioinformatics analysis revealed that the expression levels of KRT17 were higher in T compared with N tissues. (C) Immunohistochemical staining from The Human Protein Atlas demonstrated higher KRT17 expression levels in PAC compared with normal samples. (D and E) Kaplan-Meier survival analyses from the GEPIA website showed that (D) overall survival and (E) disease-free survival of patients with high expression levels of KRT17 were significantly lower compared with those with low expression levels of KRT17 in PAC. *P<0.05, ***P<0.001. KRT17, Keratin 17; PAC, pancreatic cancer; T, tumor; N, normal; HR, hazard ratio.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 expression levels in PAC tissue samples. (A) Quantitative PCR results demonstrated significantly increased expression levels of KRT17 mRNA in PAC tissues compared with adjacent normal tissues. n=18. (B) Bioinformatics analysis revealed that the expression levels of KRT17 were higher in T compared with N tissues. (C) Immunohistochemical staining from The Human Protein Atlas demonstrated higher KRT17 expression levels in PAC compared with normal samples. (D and E) Kaplan-Meier survival analyses from the GEPIA website showed that (D) overall survival and (E) disease-free survival of patients with high expression levels of KRT17 were significantly lower compared with those with low expression levels of KRT17 in PAC. *P<0.05, ***P<0.001. KRT17, Keratin 17; PAC, pancreatic cancer; T, tumor; N, normal; HR, hazard ratio.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Immunohistochemical staining, Staining

Efficient KRT17 silencing in human PANC-1 cells using KRT17-shRNA-mediated RNA interference. (A and B) Expression levels of KRT17 (A) mRNA and (B) protein in the PAC cell lines MIA PaCa-2, PANC-1 and KP-3 were significantly higher compared with the immortal ductal epithelial H6c7 cells. (C) Representative images of GFP expression in PANC-1 cells after transfection with Scr-shRNA, KRT17-shRNA-1 or KRT17-shRNA-2 lentiviruses. (D and E) KRT17 mRNA expression following transfection with KRT17-shRNA-1 or KRT17-shRNA-2 was downregulated compared with that in cells transfected with the Scr-shRNA lentivirus. GAPDH was used as the internal control. (F and G) Expression levels of KRT17 protein in PANC-1 cells following lentiviral transfection KRT17-shRNA-1 or KRT17-shRNA-2 were decreased compared with Scr-shRNA. **P<0.01. KRT17, Keratin 17; PAC, pancreatic cancer; Scr, scrambled; sh, short hairpin.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: Efficient KRT17 silencing in human PANC-1 cells using KRT17-shRNA-mediated RNA interference. (A and B) Expression levels of KRT17 (A) mRNA and (B) protein in the PAC cell lines MIA PaCa-2, PANC-1 and KP-3 were significantly higher compared with the immortal ductal epithelial H6c7 cells. (C) Representative images of GFP expression in PANC-1 cells after transfection with Scr-shRNA, KRT17-shRNA-1 or KRT17-shRNA-2 lentiviruses. (D and E) KRT17 mRNA expression following transfection with KRT17-shRNA-1 or KRT17-shRNA-2 was downregulated compared with that in cells transfected with the Scr-shRNA lentivirus. GAPDH was used as the internal control. (F and G) Expression levels of KRT17 protein in PANC-1 cells following lentiviral transfection KRT17-shRNA-1 or KRT17-shRNA-2 were decreased compared with Scr-shRNA. **P<0.01. KRT17, Keratin 17; PAC, pancreatic cancer; Scr, scrambled; sh, short hairpin.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: shRNA, Expressing, Transfection, Control

KRT17 knockdown inhibits cell proliferation in human PANC-1 cells. (A) Cell proliferation in human PANC-1 cells after transfection of lentiviral KRT17-shRNA-1 was relatively stable for 5 consecutive days compared with the Scr-shRNA group on corresponding days as determined by MTT assay. (B) Cell proliferation in human PANC-1 cells after transfection of lentiviral KRT17-shRNA-2 continued to decline for 5 consecutive days compared with the Scr-shRNA group on corresponding days. **P<0.01. KRT17, Keratin 17; Scr, scrambled; sh, short hairpin.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 knockdown inhibits cell proliferation in human PANC-1 cells. (A) Cell proliferation in human PANC-1 cells after transfection of lentiviral KRT17-shRNA-1 was relatively stable for 5 consecutive days compared with the Scr-shRNA group on corresponding days as determined by MTT assay. (B) Cell proliferation in human PANC-1 cells after transfection of lentiviral KRT17-shRNA-2 continued to decline for 5 consecutive days compared with the Scr-shRNA group on corresponding days. **P<0.01. KRT17, Keratin 17; Scr, scrambled; sh, short hairpin.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Knockdown, Transfection, shRNA, MTT Assay

KRT17 silencing arrested the cell cycle at the G 0 /G 1 phase. (A) Representative images of the cell cycle distribution in PANC-1 cells transfected with the KRT17-shRNA-1 or Scr-shRNA lentivirus. (B) Proportion of total cells at different phases of the cell cycle following transfection with KRT17-shRNA-1 or Scr-shRNA lentivirus. (C) Representative images of the cell cycle distribution in PANC-1 cells transfected with the KRT17-shRNA-2 or Scr-shRNA lentivirus. (D) Proportion of total cells at different phases of the cell cycle following transfection with KRT17-shRNA-2 or Scr-shRNA lentivirus. **P<0.01. KRT17, Keratin 17; Scr, scrambled; sh, short hairpin.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 silencing arrested the cell cycle at the G 0 /G 1 phase. (A) Representative images of the cell cycle distribution in PANC-1 cells transfected with the KRT17-shRNA-1 or Scr-shRNA lentivirus. (B) Proportion of total cells at different phases of the cell cycle following transfection with KRT17-shRNA-1 or Scr-shRNA lentivirus. (C) Representative images of the cell cycle distribution in PANC-1 cells transfected with the KRT17-shRNA-2 or Scr-shRNA lentivirus. (D) Proportion of total cells at different phases of the cell cycle following transfection with KRT17-shRNA-2 or Scr-shRNA lentivirus. **P<0.01. KRT17, Keratin 17; Scr, scrambled; sh, short hairpin.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Transfection, shRNA

KRT17 knockdown increases apoptosis in human PANC-1 cells. (A) Representative fluorescence of PANC-1 cells infected with the Scr-shRNA, KRT17-shRNA-1 or KRT17-shRNA-2 lentivirus. (B) Proportion of apoptotic PANC-1 cells was increased following KRT17-shRNA-1 knockdown compared with the Scr-shRNA group. (C) Proportion of apoptotic PANC-1 cells following KRT17-shRNA-2 knockdown was elevated compared with the control cells. **P<0.01. KRT17, Keratin 17; sh, short hairpin.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 knockdown increases apoptosis in human PANC-1 cells. (A) Representative fluorescence of PANC-1 cells infected with the Scr-shRNA, KRT17-shRNA-1 or KRT17-shRNA-2 lentivirus. (B) Proportion of apoptotic PANC-1 cells was increased following KRT17-shRNA-1 knockdown compared with the Scr-shRNA group. (C) Proportion of apoptotic PANC-1 cells following KRT17-shRNA-2 knockdown was elevated compared with the control cells. **P<0.01. KRT17, Keratin 17; sh, short hairpin.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Knockdown, Fluorescence, Infection, shRNA, Control

KRT17 knockdown inhibits colony formation in human PANC-1 cells. (A) Giemsa staining of PANC-1 clones in 6-well plates 14 days post-transfection with the Scr-shRNA or KRT17-shRNA-1 lentiviruses. (B) Mean number of PANC-1 colonies counted following KRT17-shRNA-1--mediated knockdown was decreased compared with the corresponding Scr-shRNA groups. (C) Giemsa staining of PANC-1 clones in 6-well plates 14 days post-transfection with the Scr-shRNA or KRT17-shRNA-2 lentiviruses. (D) Mean number of PANC-1 colonies counted following KRT17-shRNA-2-mediated knockdown was decreased compared with the corresponding Scr-shRNA groups. **P<0.01. KRT17, Keratin 17; sh, short hairpin; Scr, scrambled.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 knockdown inhibits colony formation in human PANC-1 cells. (A) Giemsa staining of PANC-1 clones in 6-well plates 14 days post-transfection with the Scr-shRNA or KRT17-shRNA-1 lentiviruses. (B) Mean number of PANC-1 colonies counted following KRT17-shRNA-1--mediated knockdown was decreased compared with the corresponding Scr-shRNA groups. (C) Giemsa staining of PANC-1 clones in 6-well plates 14 days post-transfection with the Scr-shRNA or KRT17-shRNA-2 lentiviruses. (D) Mean number of PANC-1 colonies counted following KRT17-shRNA-2-mediated knockdown was decreased compared with the corresponding Scr-shRNA groups. **P<0.01. KRT17, Keratin 17; sh, short hairpin; Scr, scrambled.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Knockdown, Staining, Clone Assay, Transfection, shRNA

KRT17 knockdown inhibits the migration of human PANC-1 cells. (A) Representative images of migratory PANC-1 cells transfected with the KRT17-shRNA-1 lentivector. (B) The number of migrated PANC-1 cells transfected with the KRT17-shRNA-1 lentivector was significantly decreased compared with the Scr-shRNA group. **P<0.01. KRT17, Keratin 17; sh, short hairpin; Scr, scrambled.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 knockdown inhibits the migration of human PANC-1 cells. (A) Representative images of migratory PANC-1 cells transfected with the KRT17-shRNA-1 lentivector. (B) The number of migrated PANC-1 cells transfected with the KRT17-shRNA-1 lentivector was significantly decreased compared with the Scr-shRNA group. **P<0.01. KRT17, Keratin 17; sh, short hairpin; Scr, scrambled.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Knockdown, Migration, Transfection, shRNA

KRT17 silencing inhibits tumor growth in vivo . (A) Changes in tumor volume after injection of PANC-1 cells transfected with the KRT17-shRNA-1 or Scr-shRNA lentivector. (B) The diameter of PANC-1 tumors was lower in the KRT17-shRNA-1 group compared with the Scr-shRNA group 5 weeks after transplantation. (C) Mean tumor weight was reduced in the KRT17-shRNA-1 group compared with the Scr-shRNA group 5 weeks after cell injection. n=10. *P<0.05. KRT17, Keratin 17; sh, short hairpin; Scr, scrambled.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: KRT17 silencing inhibits tumor growth in vivo . (A) Changes in tumor volume after injection of PANC-1 cells transfected with the KRT17-shRNA-1 or Scr-shRNA lentivector. (B) The diameter of PANC-1 tumors was lower in the KRT17-shRNA-1 group compared with the Scr-shRNA group 5 weeks after transplantation. (C) Mean tumor weight was reduced in the KRT17-shRNA-1 group compared with the Scr-shRNA group 5 weeks after cell injection. n=10. *P<0.05. KRT17, Keratin 17; sh, short hairpin; Scr, scrambled.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: In Vivo, Injection, Transfection, shRNA, Transplantation Assay

Effects of KRT17 knockdown on cell proliferation-related signaling molecules in PANC-1 cells. (A) Levels of proliferation-related signaling molecules were measured by quantitative PCR. Unpaired t-test. (B) The levels of pERK1/2, p-Akt, p-p38 MAPK and Bad expression following KRT17 knockdown. (C) Quantitative analysis of the grey value of (B). **P<0.01. Keratin 17; Scr, scrambled; p-, phosphor; sh, short hairpin; JNK, C-Jun N-terminal kinase 1.

Journal: Oncology Letters

Article Title: Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells

doi: 10.3892/ol.2020.11469

Figure Lengend Snippet: Effects of KRT17 knockdown on cell proliferation-related signaling molecules in PANC-1 cells. (A) Levels of proliferation-related signaling molecules were measured by quantitative PCR. Unpaired t-test. (B) The levels of pERK1/2, p-Akt, p-p38 MAPK and Bad expression following KRT17 knockdown. (C) Quantitative analysis of the grey value of (B). **P<0.01. Keratin 17; Scr, scrambled; p-, phosphor; sh, short hairpin; JNK, C-Jun N-terminal kinase 1.

Article Snippet: Two short hairpin RNA (shRNA) sequences specifically targeting KRT17 (GeneBank ID: X62571.1; 5′-CAGTCGCGTTTGCGACTGG-3′ and 5′-CTTCCTTGCCTGATGACAA-3′) and a scrambled (Scr) shRNA sequence (5′-TTCTCCGAACGTGTCACGT-3′) for use as a negative control were designed and purchased from iGene Biotechnology Co., Ltd.

Techniques: Knockdown, Real-time Polymerase Chain Reaction, Expressing